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The prevalence of type 2 diabetes mellitus is increasing due to the combination of 
ageing of the population and the pandemic increase in overweight and obesity [1, 2]. 
About one third of patients with diabetes develops diabetic nephropathy, which is 
the most common cause for chronic kidney disease [3]. This is associated with a huge 
burden of disease, in terms of human suffering as well as health care expenditure 
[4, 5]. A better knowledge of risk factors for diabetic nephropathy and early detection 
of patients at risk for diabetic renal disease, as well as early initiation of appropriate 
treatment could reduce the morbidity and mortality associated with this major 
health problem.
Pathogenesis of diabetic nephropathy
The pathogenesis of diabetic nephropathy is complex, and essentially driven by 
exposure of the kidneys to an altered internal milieu, that triggers multiple pathways 
of disease [6, 7]. Within the kidney, hyperglycemia induces glomerular hyperfiltration 
and endothelial dysfunction, leading to changes in basement membrane properties, 
intraglomerular cellular hypertrophy and hyperplasia, nodular intercapillary 
glomerulosclerose (Kimmelstiel-Wilson lesion), and glomerular matrix changes, 
clinically often detectable by albuminuria [8, 9]. This is usually associated with 
volume expansion and hypertension, due to increased tubular sodium reabsorption. 
The increased tubular protein load, by uptake in proximal tubular cells, triggers a pro-
inflammatory tubulo-interstitial response leading to progressive tubulo-interstitial 
inflammation and fibrosis, which is also accelerated by hyperglycemia itself 
[10, 11]. In patients with diabetes, an inappropriately elevated activity of the renin-
angiotensin-aldosterone system (RAAS) also plays a main role in these processes by 
its effect on systemic and glomerular pressure, its effect on sodium handling, and by 
direct pro-fibrotic effects of angiotensin II and aldosterone [12, 13].
Futhermore, glycation of tissue proteins is thought to contribute to development 
of diabetic nephropathy and other microvascular complications. In hyperglycemic 
states, excess glucose binds to free amino acids on circulating or tissue proteins, 
leading to a nonenzymatic reactions resulting in reversible glycation products, and 
in a later stage in advanced glycation endproducts (AGEs), stable and often long 





































tissues, including the kidney [14]. Interaction between AGEs and AGE-receptors plays 
a role in induction of inflammation and endothelial dysfunction [15]. Thus, tissue 
accumulation of AGEs is not just a measure of prevailing hyperglycemia, but also 
represents cumulative metabolic burden, oxidative stress (overload of superoxides 
and cellular pseudohypoxia) and inflammation [16]. Interestingly, AGE accumulation 
has been shown to precede and correlate with early manifestation of renal disease 
in diabetes [17, 18].
Genetic risk factors for diabetic nephropathy
In addition to the well-known risk factors of diabetic nephropathy (age, obesity, 
smoking, hypertension and duration of diabetes), genetic factors have been suggested 
to be important determinants of the predisposition to diabetic nephropathy [19, 20]. 
Evidence from family-based linkage studies showed that diabetic nephropathy is more 
prevalent in some families while other families seem protected and led to identify 
susceptibility loci and map them to different chromosomes [21, 22]. A few candidate 
genes, such as Angiotensin-converting enzyme (ACE) gene, endothelial nitric oxide 
synthase (NOS3) gene, Erythropoietin (EPO) gene, and Apolipoprotein L1 (APOL1) 
gene have been reproducibly associated with diabetic nephropathy and recent 
genome-wide linkage studies have also identified chromosomal loci for susceptibility 
genes, including 3q, 7q, 10p, 14q and 18q [23-26]. Although the individual 
contribution of these genes to the variability in incidence of diabetic nephropathy 
appears to be small, genetic studies may still provide valuable information regarding 
the pathophysiology of nephropathy and potential targets for its treatment [27].
CNDP1
Several candidate genes provide promising prospects. Recently, an allelic variant 
within the leader peptide of carnosinase gene (CNDP1) was suggested to be associated 
with diabetic nephropathy by influencing the carnosine pathway [28]. This gene 
encodes the enzyme serum carnosinase, which hydrolyses the substrate L-carnosine 
(β-alanyl-L-histidine). Carnosine is a dipeptide that is present intracellularly in 
most tissues, with the highest levels found in muscles, where it is released into 






































first described to function as a natural inhibitor of angiotensin-converting enzyme 
(ACE) and advanced glycation endproducts (AGEs), as well as a scavenger of radical 
oxygen species (ROS) [30, 31]. Cell culture and animal experiments have shown that 
L-Carnosine can influence glucose metabolism and inhibit effects of high glucose 
on mesangial cells, and could thereby play a role in the cascades of inflammation 
and oxidative stress which are supposed to contribute to the development of 
microvascular complications in diabetes [28, 32]. The gene variant with the lowest 
number of leucine repeat (5L-5L) in CNDP1 gene has been found to be associated 
with a lower prevalence of diabetic nephropathy compared to variants with more 
leucine repeats (i.e., 5L-6L, 6L-6L, 6L-7L, 5L-7L or 7L-7L) [28, 33]. However, data are 
conflicting and prospective, longitudinal studies on this gene are scarce [34].
CCR2
Genetic variation in chemokine pathways has also been shown to modulate the 
outcome in inflammation-driven vascular disease, including diabetic nephropathy, 
as demonstrated for gene of the chemokine receptor-5 (CCR5) [35]. CCR2 is another 
chemokine receptor which may act as coreceptor for macrophage [36]. Genetic 
variation in CCR2, i.e CCR-V64I is suggested to have a role in the inflammatory 
pathway by modulating monocyte chemoattractant protein-1 (MCP-1)-receptors, 
hence modifying cardiovascular outcome in several populations [37, 38]. This SNP 
has however not yet been studied in patients with diabetes.
Prediction and diagnosis of diabetic nephropathy
Although many risk factors for developing diabetic nephropathy have been identified, 
none is yet sufficiently predictive in the individual patient. Microalbuminuria, defined 
as urinary albumin excretion between 30 and 300 mg/day, or albumin creatinine 
ratio of 2.5 to 25 mg/mmol in males and 3.5 to 35 mg/mmol in females in a random 
urine sample, is the earliest detectable sign of diabetic nephropathy and is also a 
predictor of risk of progressive renal disease and mortality in patients with type 1 
and type 2 diabetes [39, 40]. Although guidelines recommend the use of albuminuria 
as a screening tool for renal disease in diabetes, its specificity is still a subject of 





































is also associated with general vascular damage. Thus, when albuminuria is already 
established, it is a sign of substantial organ damage, not only of the kidneys, but also 
of other organs such as the heart and the arterial vascular system. 
Alternative non-invasive methods that may detect diabetic nephropathy at earlier 
stages would be beneficial to start early treatment and thereby to delay or prevent 
progression of chronic kidney disease. In the last decades, novel urinary markers 
of renal damage such as kidney injury molecule-1 (KIM-1), α-1 microglobulin and 
neutrophil gelatinase-associated lipocalin (NGAL), have been discovered and 
investigated as potential predictors of acute and chronic kidney disease [42-44].
Additionally, urinary proteome analysis, as measured by Capillary Electrophoresis 
coupled Mass Spectrometry (CE-MS), is a non invasive means to identify biomarkers 
of early damage in many conditions, including renal disease [45, 46]. The urinary 
proteome contains an array of stable low molecular proteins and peptides, which 
could function as a powerful diagnostic and prognostic tool in chronic kidney disease 
and diabetic nephropathy [47, 48]. In a recent study, 65 biomarkers of diabetic 
nephropathy were identified with urinary proteome analysis using CE-MS. This 
model of 65 biomarkers, independently validated in another cohort (n=70), correctly 
identified patients with diabetic nephropathy with 97% sensitivity and specificity [49]. 
Confirmation of the diagnostic value of the identified urine biomarkers is however 
necessary before the assessment of urinary proteome can be used in clinical practice 
[50].
Treatment of diabetic nephropathy
Tight glycaemic control has been shown to reduce the risk for development of 
albuminuria in patients with diabetes, as shown in several controlled trials in type 
1 and type 2 diabetes [51, 52]. However, once established, glomerular lesions and 
albuminuria are poorly reversible and glycaemic control has, therefore, only limited 
influence on progression to end-stage renal disease (ESRD) once albuminuria is 
present [53].
Blockade of the RAAS by angiotensin-converting enzyme inhibitors (ACE-Is) and 
angiotensin receptor blockers (ARBs) is currently the cornerstone of preventing the 






































risk for decline in renal function were approximately 50% with ACE-I treatment in 
patients with type 1 diabetes (25/207 in the Captopril group compared to 43/202 in 
the placebo group) [55]. These risk reductions were considerably less – approximately 
15% – for the end-point of doubling of serum creatinine or reaching ESRD in type 
2 diabetic patients with diabetic nephropathy (327/751 in the Losartan group 
compared to 359/762 in the placebo group) [57]. 
Several strategies to improve the efficacy of RAAS-blockade-based regimens have 
been proposed, including higher dosing, and dual or even triple RAAS-blockade [58-
60]. However, the long term effects of such combinations on renal or cardiovascular 
outcomes have not yet been evaluated in clinical trials and they are associated with 
increased risk for hyperkalemia. Taken together, the current data seem to indicate 
that intensification of reduction of blood pressure and albuminuria has its limits, 
and accordingly, there is a need for further adjunctive treatments, interfering with 
pathways of disease not targeted with current therapy, that can prevent progressive 
decline in renal function in patients with diabetic nephropathy, in type 2 diabetes in 
particular. 
In animal and experimental studies, benfotiamine, a lipid-soluble thiamine derivative, 
has been shown to be able to block three major pathways of hyperglycemic 
damage: the hexosamine pathway, AGE formation pathway and the diacylglycerol 
(DAG)-protein kinase C (PKC) pathway. Benfotiamine has also been shown to block 
hyperglycemia-associated pro-inflammatory transcription factor NF-κB activation 
[61]. These pathways, when activated by hyperglycemia, result in accumulation of 
triphosphates and overproduction of superoxides, inducing metabolic pseudohypoxia, 
mitochondrial dysfunction and oxidative stress in renal and endothelial cells, finally 
leading to vascular damage [7]. Thiamine and benfotiamine inhibited these pathways 
by activating the enzyme transketolase (TK), which converts glyceraldehydes-3-
phospate and fructose-6-phosphate into pentose-5-phosphates and other sugars. It 
has therefore been suggested that thiamine and benfotiamine are able to oppose 
diabetic vascular complications, including diabetic nephropathy [61, 62]. An animal 
study performed in 2003 has shown that high dose of thiamine and benfotiamine 
prevented microalbuminuria and proteinuria [62]. A recent pilot study has suggested 





































excretion in Pakistani patients with type 2 diabetes and microalbuminuria [63]. 
Randomized controlled trials in patients with diabetes are however necessary to 
answer the question whether benfotiamine will decrease albuminuria or ameliorate 
the effects of both hyperglycemia and albuminuria on AGE accumulation, and 
thereby decrease inflammatory and fibrotic responses, whereby it could potentially 
slow down the progression to ESRD.
Aim of the thesis
In this thesis, several novel risk prediction and intervention aspects in diabetic 
nephropathy are evaluated. First, genetic variations in CNDP1 and CCR2 genes and 
their associations with progression of diabetic renal disease and/or mortality in 
patients with diabetes were investigated. Second, the value of urinary proteomic 
biomarkers as a diagnostic tool for identifying patients with diabetic nephropathy 
was investigated. Third, a randomized controlled trial was performed to investigate 
whether treatment with benfotiamine could be a beneficial intervention for diabetic 
nephropathy in patients with type 2 diabetes.
 
Outline of the thesis
In Chapters 2 and 3, two prospective studies on CNDP1 gene were performed in 
order to investigate the associations of this polymorphism with progression of 
diabetic renal disease (progression of decline in renal function or development of 
ESRD) and/or mortality in patients with diabetes. It was also explored whether the 
association between 5L-5L genotype of CNDP1 gene and diabetic nephropathy is sex-
specific, as suggested by a recent cross-sectional study [64].
 
In Chapter 2, these questions were investigated in a multi-center cohort of European 
patients with type 1 diabetes from Denmark, Finland and France (EURAGEDIC study). 
In this study, 2086 patients were included. 916 patients had diabetic nephropathy 
(cases) and 1170 patients had diabetes without nephropathy (controls). These 
patients were prospectively followed for a median period of 8.8 years. In Chapter 
3, the same questions were investigated in patients with type 2 diabetes from the 






































was initiated in 1998 as a large shared-care diabetes project in which hospital-based 
nurses specialized in diabetes assist general practitioners in caring for patients with 
type 2 diabetes. From a total of 1143 patients, blood samples from 913 patients were 
available for future research, including genetic studies. Data on mortality (total and 
cardiovascular mortality) were gathered in 2008 after a median follow-up period of 
9.6 years.
In Chapter 4, the association between the CCR2-V64I polymorphism and the 
development of diabetic nephropathy was investigated. It was also investigated 
to which extent this SNP adds to the risk carried by the well known ACE I/D 
polymorphism. For this purpose, we performed a prospective analysis in 1128 
patients from the BErgamo NEphrologic Diabetic Complications Trial (BENEDICT) 
– a prospective randomized trial evaluating the effect of ACE-I on new-onset 
microalbuminuria (albuminuria 20-200 µg/min) in hypertensive type 2 diabetes 
patients without albuminuria (<20 µg/min) at inclusion. In total, 1124 patients were 
genotyped according to ACE I/D and CCR2-V64I polymorphisms and followed until 
the development of new-onset microalbuminuria during a median period of 42 
months.
In Chapter 5, the diagnostic value of urinary proteomic analysis in diabetic 
nephropathy was validated by investigating the diabetic nephropathy biomarker 
classifier derived from 65 biomarkers, which were identified in a previous study 
[49]. This was performed in urine of 148 Caucasian patients with type 2 diabetes 
from Zwolle (The Netherlands), Graz (Austria) and Prague (Czech Republic), who 
participated in a case-control study. For the diagnosis of diabetic nephropathy, 
urinary proteome analysis was successfully applied in a pilot study. We therefore 
aimed to confirm whether this tool could adequately identify subjects with diabetes 
nephropathy.
In Chapters 6 and 7, It was investigated whether a three-month treatment with 
benfotiamine would be able to prevent progression of diabetic nephropathy in 





































controlled clinical trial was performed in patients with type 2 diabetes and albuminuria 
to examine the effects of benfotiamine on urinary albumin excretion and excretion 
of urinary markers of tubular damage (Chapter 6). It was also investigated whether 
benfotiamine treatment reduced the formation of AGEs, markers of endothelial 
damage and inflammation (Chapter 7).
In Chapter 8, I summarize the results of all performed studies. I also discuss the 
implications, strengths and limitations, as well as future perspectives of the studies 
presented in this thesis.
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Chapter 2
A polymorphism in the gene encoding carnosinase 
(CNDP1) as a predictor of mortality and progression from 
nephropathy to end-stage renal disease in type 1 diabetes
Alkhalaf A, Bakker SJL, Bilo HJG, Gans ROB, Navis GJ, Postmus D, Forsblom D, Groop 








































Homozygosity for a 5-leucine repeat (5L–5L) in the carnosinase gene (CNDP1) 
was found to be cross-sectionally associated with a low frequency of diabetic 
nephropathy (DN), mainly in type 2 diabetes. We prospectively investigated in 
patients with type 1 diabetes whether: (1) 5L–5L is associated with mortality; 
(2) there is an interaction of 5L–5L with DN or sex for prediction of mortality; 
and (3) 5L–5L is associated with progression to end-stage renal disease (ESRD). 
Methods
In this prospective study in white European patients with type 1 diabetes, individuals 
with DN were defined by persistent albuminuria ≥ 300 mg/24 h. Controls without 
nephropathy were defined by persistent (>15 years) normoalbuminuria <30 mg/24 
h. Leucine repeats were assessed with a fluorescent DNA analysis system. Onset 
of ESRD was defined by need to start chronic dialysis or kidney transplantation. 
Results
The study involved 916 patients with DN and 1170 controls. During follow-up for 
8.8 years, 107 patients (14%) with 5L–5L died compared with 182 patients (13.8%) 
with other genotypes (p=0.99). There was no significant interaction of 5L–5L with 
DN for prediction of mortality (p=0.57), but a trend towards interaction with sex 
(p=0.08). In cases with DN, HR for ESRD in 5L–5L vs other genotypes was not constant 
over time, with increased risk for 5L–5L beyond 8 years of follow-up (p=0.03). 
Conclusions
CNDP1 polymorphism was not associated with mortality, and nor was there an 
interaction of this polymorphism with DN for prediction of mortality in patients with 
type 1 diabetes. CNDP1 polymorphism predicts progression to ESRD in patients with 







































Diabetes is the leading cause of end-stage renal disease (ESRD) in the western world. 
In the last decade, diabetic patients in the USA and Europe accounted for 40% and 
26% of the populations receiving dialysis, respectively [1-3]. Poor glycaemic control 
and high blood pressure are acknowledged contributors to the pathophysiology of 
diabetic nephropathy (DN) [4], but epidemiological and familial studies have suggested 
genetic predisposition to be involved as well [5-7]. Analyses of family-based studies 
in Turkish, Pima Indian and African-American patients with type 2 diabetes have 
mapped a major susceptibility locus to chromosome 18 [8, 9]. In a cross-sectional 
study in patients with type 1 and type 2 diabetes, this locus was identified as the 
carnosinase gene 1 (CNDP1); homozygosity for five copies of a trinucleotide repeat 
encoding leucine (5L–5L) in this gene was found to be more common in patients 
without DN than in those with DN [10]. This finding was confirmed by findings 
from other cross-sectional studies in patients with type 2 diabetes [11, 12] and 
has been suggested to be consistent with a protective role of the 5L–5L genotype 
against DN, particularly in women [13]. However, these findings from cross-sectional 
studies could be subject to selection bias. They could, for instance, be explained 
by a possible interaction of 5L–5L genotype with DN, sex or both for prediction of 
mortality. Survival (dis)advantages in subgroups may induce false associations in 
cross-sectional studies [14].
In this observational study in a white European cohort of patients with type 1 
diabetes, we therefore aimed to investigate prospectively: (1) the association of 
CNDP1 gene polymorphism with mortality; (2) a potential interaction of this gene 
polymorphism with DN or sex for prediction of mortality; and (3) an association of 







































The present study included patients from three European coordinating centres in 
Denmark, Finland and France. All the individuals included were of European descent. 
In Denmark between 1993 and 2000, all Danish patients with type 1 diabetes 
attending the outpatient clinic at Steno Diabetes Center were invited to participate in 
a study of genetic risk factors for micro- and macrovascular complications of diabetes 
[15]. In France and Belgium, 17 diabetes clinics participated in a study of the genetic 
risk factors for diabetes complications between 1994 and 2001, which included 
eligible patients with type 1 diabetes [16, 17]. In Finland, between 1994 and 2002, 
patients with type 1 diabetes were recruited from 56 referral centres to participate 
in the prospective Finnish Diabetic Nephropathy Study (FinnDiane).
Type 1 diabetes was considered present if the age at onset of diabetes was ≤ 35 years 
and the time to definitive insulin therapy ≤ 1 year. Established diabetic nephropathy 
(cases) was defined by persistent albuminuria (>300mg/24h or >200μg/min or 
>200mg/l) in two out of three consecutive measurements made on sterile urine 
samples, after >5 years’ diabetes duration. In patients using ongoing regimens of 
angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin-receptor blocker 
(ARB), the last measurements of urinary albumin excretion before treatment initiation 
were used for classification. Patients with clinical suspicion of non-diabetic renal or 
urinary tract disease were excluded. Absence of diabetic nephropathy (controls) was 
defined as persistent normoalbuminuria (urinary AER [uAER] <30 mg/24 h or <20 
μg/min or <20mg/l) after at least 15 years of diabetes in patients not treated with 
ACE-Is or ARBs.
The study was performed in accordance with the Helsinki Declaration. The local 
ethics committee approved the study and all patients gave their informed consent.
Baseline clinical laboratory investigations
All patients had blood samples and phenotypic characteristics collected as part of the 
European Rational Approach for the Genetics of Diabetic Complications (EURAGEDIC) 
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determined by standard HPLC techniques with normal values in the range 4.1% to 
6.4%. Plasma creatinine concentration was determined by modified Jaffe’s method. 
Timed urine collections were used to obtain uAER. Diabetic retinopathy was assessed 
by fundus photography or direct ophthalmoscopy carried out by an experienced 
ophthalmologist. Based on standardised questionnaires, former or current smokers of 
one or more cigarettes/cigars/pipes per day were classified as smokers and all others 
as non-smokers. Non-fatal cardiovascular disease was considered present in patients 
with a history of admission for stroke, myocardial infarction or vascular amputations. 
DNA material was genotyped as part of the EURAGEDIC project as follows. Genomic 
DNA was isolated from human leucocytes using standard methods. D18S880 marker 
genotyping was performed at the French National Genotyping Centre using an 
automated high-throughput method. All liquid handling was performed robotically 
in 384 well plates with a BasePlate Robot (The Automation Partnership, Royston, 
UK). PCR amplification was carried out in a 5µl volume with 5 ng of genomic DNA and 
primers AGGCAGCTGTGTGAGGTAAC (forward) labelled with the fluorescent dye Fam 
and GGGTGAGGAGAACATGCC (reverse) using a standard protocol. The annealing 
temperature was 55°C. Fluorescent PCR products were analysed on a MegaBace TM 
1000 Sequencer (Amersham Biosciences, Buckinghamshire, UK) using appropriate 
software. Automatic genotyping was performed using Genetic Profiler software 
(version 3.1). Before statistical analysis, rigorous genotype quality assurance was 
performed to ensure accurate binning of alleles. Three alleles were observed with 
fragment sizes of 167, 170 and 173 base pairs corresponding to 5-, 6- and 7-leucine 
repeats respectively. The 5L–5L homozygous genotype was compared with all other 
genotypes (i.e. genotypes with six or more leucine repeats).
follow-up 
In this prospective observational study, patients were followed: until an endpoint was 
reached; to the last visit at the outpatient department; or until 1 September 2006 
for the Danish population, 1 December 2009 for the Finnish population or 1 February 
2007 for the French population. The endpoints were all-cause mortality and ESRD, 
defined as need to start chronic dialysis or kidney transplantation. All patients were 





































of death was recorded. Information about date of ESRD was obtained from patient 
records or discharge letters from other hospitals.
Statistical analysis 
Variables with normal distribution are presented as mean ± SD and variables with 
skewed distribution were log-transformed before analysis and presented as median 
and interquartile range (IQR). For variables with normal distribution, comparisons 
between groups were performed using unpaired Students t tests, whereas for 
variables with skewed distribution Mann–Whitney U tests were used. χ2 tests were 
used to compare non-continuous variables. Time-to-event analyses were performed 
using Kaplan–Meier plots and logrank testing. Tests for a non-zero slope of scaled 
Schoenfeld residuals on functions of time were performed to explore the proportional 
hazards (PH) assumption in Cox regression models [19]. If the PH assumption was 
met (test based on Schoenfeld residuals p > 0.05), Cox regression models were used 
to estimate unadjusted and adjusted hazard ratios with 95% confidence intervals. 
Otherwise, Cox models with time-dependent covariates were used to calculate 
HRs over time [20]. After an initial crude analysis, two subsequent models were 
constructed in which the associations were adjusted for potential confounders and 
covariates defined a priori. In the first multivariate model, adjustment was performed 
for age, sex and centre of inclusion. In the other model, further adjustment was 
performed for duration of diabetes, HbA1c, blood pressure, plasma creatinine and 
uAER. In this study, we were able to detect a genotype relative risk for mortality of 
1.2 with a power of 95% at the level of significance p = 0.05. In those with DN, we 
were able to detect a genotype RR for ESRD of 1.3 with a power of 95% at p= 0.05. 
The PS program of Dupont and Plummer [21] was used to calculate power. Analysis 
of the Danish, Finnish and French populations separately gave comparable results, 
and thus pooled data are presented.
A two-tailed p value of 0.05 or less was considered statistically significant. Statistical 
analyses were done by using a commercially available program (SPSS for Windows, 








































In total, 2487 patients (900 from Denmark, 687 from France and 900 from Finland) 
were included. The CNDP1 genotype could not be determined in 401 patients: DNA 
samples from 74 patients from France were missing, and poor-quality DNA samples 
were obtained from 65 patients from Denmark, 88 patients from France and 174 from 
Finland. The baseline characteristics of these patients were not significantly different 
from those who were genotyped. Table 1 shows the baseline characteristics of the 
study population (n = 2086). Patients with DN were younger, more commonly men, 
and had higher HbA1c, blood pressure and serum creatinine levels than controls. The 
frequency of the 5L–5L genotype was not significantly different between patients 
with DN and patients without DN [22] and also not between men and women. The 
OR for the presence of DN according to 5L–5L genotype was 0.99 (95% CI 0.82-1.18) 
for the whole population, with an OR of 1.05 (95% CI 0.83-1.34) for men and 0.90 
(95% CI 0.69-1.18) for women (p = 0.40 for interaction).
Prospective analyses for mortality 
Median (IQR) follow-up was 8.8 (6.1-10.5) years. Of patients with DN, 81 of 334 
patients (24.3%) with 5L–5L died during the follow-up vs 142 of 582 patients (24.4%) 
with other genotypes (logrank test p =0.73). In controls without DN, these numbers 
were 26 of 430 (6.0%) and 40 of 740 (5.4%), respectively (logrank test p = 0.66). 
The PH assumption for Cox regression was met (test based on Schoenfeld residuals, 
p = 0.17). After adjustment for potential confounders, including age, sex, blood 
pressure and history of cardiovascular events in Cox regression analyses, HR for 
mortality in 5L–5L vs other genotypes was 0.95 (95% CI 0.73-1.22, p = 0.67).
There was no significant interaction between 5L–5L and presence of DN for prediction 
of mortality (p = 0.57). However, there was a trend towards interaction between 5L–
5L and sex for prediction of mortality (p = 0.08). After stratification for sex, adjusted 
HR for mortality in 5L–5L vs other genotypes was 0.87 (95% CI 0.62-1.21, p = 0.41) in 
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Prospective analyses for end-stage renal disease 
No events occurred in controls without nephropathy. We therefore limited further 
analyses to patients with DN (n = 916). At baseline, 52 patients were already 
diagnosed with ESRD and were not included in the prospective analyses.
During follow-up, 77 out of 312 patients (24.7%) with 5L–5L developed ESRD vs 121 
of 552 (21.9%) patients with other genotypes. Figure 1 shows a Kaplan–Meier plot 
of development of ESRD according to CNDP1 genotype (logrank test p =0.57). The 
PH assumption for Cox regression was not met (p = 0.02). Further Cox-regression 
analysis with a time-dependent covariate showed that the hazard ratio for ESRD was 
not constant over time (p = 0.03). 
Figure 1: Kaplan–Meier curves of ESRD in 864 patients with type 1 diabetes and diabetes 
nephropathy according to CNDP1 genotype: 5-leucine repeat homozygous (5L–5L) vs all other 
genotypes (logrank test p=0.57). Solid line, 5L–5L genotype; dotted line, all other genotypes
As shown in Table 2, within the first 6 years, the hazards were not significantly 
different between patients with 5L–5L genotype and those with other genotypes. 





































genotypes was 0.82 (95% CI 0.55-1.22) at 2 years of follow-up. However, after 8 years 
of follow-up, patients with the 5L–5L genotype appeared to have an increased risk 
of ESRD compared with those with other genotypes, with an HR of 1.53 (95% CI 
1.01-2.34) at 8 years of follow-up and an HR of 1.89 (95% CI 1.07-3.36) at 10 years 
of follow-up. Adjustment for possible confounders, including duration of diabetes, 
baseline glycated haemoglobin, blood pressure, plasma creatinine and urinary 
albumin excretion did not materially change the results of the analyses for 5L–5L: HR 
at 8 years, 1.71 (95% CI 1.11-2.65); and at 10 years, 2.19 (95% CI 1.21-4.01).
Table 2: Hazard ratios for ESRD from Cox models with time-dependent variables
Model/genotypes HR (95% CI)
Crude model
  Other genotypes 1.0 (Ref.)
  5L–5L genotypes
    At 1 year 0.73 (0.46-1.17)
    At 2 years 0.82 (0.55-1.22)
    At 4 years 1.01 (0.75-1.36)
    At 6 years 1.24 (0.91-1.69)
    At 8 years 1.53 (1.01-2.34)
    At 10 years 1.89 (1.07-3.36)
Adjusted for age, sex and centre
  Other genotypes 1.0 (Ref.)
  5L–5L genotypes
    At 1 year 0.75 (0.74-1.21)
    At 2 years 0.84 (0.56-1.25)
    At 4 years 1.04 (0.76-1.40)
    At 6 years 1.28 (0.94-1.75)
    At 8 years 1.59 (1.04-2.41)
    At 10 years 1.96 (1.11-3.49)
Further adjusted for duration of diabetes, HbA1c, blood 
pressure, plasma creatinine and uAER
  Other genotypes 1.0 (Ref.)
  5L–5L genotypes
    At 1 year 0.71 (0.41-1.27)
    At 2 years 0.81 (0.51-1.32)
    At 4 years 1.04 (0.73-1.49)
    At 6 years 1.34 (0.96-1.87)
    At 8 years 1.71 (1.11-2.65)
    At 10 years 2.19 (1.21-4.01)







































In this study of a large cohort of white European patients with type 1 diabetes, 
the prevalence of homozygosity for 5-leucine repeats in the CNDP1 gene was not 
significantly different between patients with DN and patients without DN at study 
entry. In prospective analyses, we found neither an association of 5L–5L with mortality 
nor an interaction of 5L–5L with DN for prediction of mortality. Patients with 5L–5L 
have shown a trend towards a sex-dependent association with risk for mortality, 
with higher risk associated with 5L–5L in women than in men, but no significant 
associations with mortality were present in the sexes separately. Patients with DN 
and 5L–5L were at increased risk of progression to ESRD compared with those with 
other allelic variations, but this increase in risk became apparent only after 8 years of 
follow-up. The increase in risk was independent of potential confounders.
In an earlier study in a large cohort of patients with type 1 diabetes and DN (n= 445), 
Wanic et al. [23]found no significant association between 5L–5L and susceptibility 
for progression to ESRD after a mean follow-up of 5.6 years. In that study, it was 
not investigated whether the proportional hazards assumption of Cox-regression 
analyses was violated. If we performed similar analyses as performed in the study of 
Wanic et al., we would have found similar results. However, taking into account the 
change in hazards over time unmasked an increased risk associated with 5L–5L after 
prolonged follow-up.
The CNDP1 gene, which is located on chromosome 18, encodes a secreted serum 
carnosinase that degrades carnosine specifically, whereas CNDP2 encodes tissue 
carnosinase [24]. Carnosine is a naturally occurring dipeptide that has been shown 
to have beneficial actions as, for example, a scavenger of free oxygen radicals and an 
inhibitor of formation of advanced glycation endproducts [25-27]. Individuals with 
genotypes containing a higher number of leucine repeats (six or seven repeats) in 
their CNDP1 gene were found to have higher serum carnosinase activity compared 
with those with five leucine repeats [28]. High serum carnosine levels resulting from 
low carnosinase activity were considered to underlie findings from cross-sectional 
studies that suggested a protective role of 5L–5L genotype against DN, mainly in type 





































Findings from cross-sectional studies should be interpreted carefully. For instance, 
interaction between 5L–5L and DN resulting in a survival disadvantage in these patients 
could falsely suggest a protective effect of 5L–5L for DN in a cross-sectional study 
[14]. Our study is the first to investigate such a potential interaction prospectively. 
We found no evidence for an interaction between 5L–5L and DN for mortality. 
Another interaction that we considered was an interaction by sex, given a recent 
finding from cross-sectional data that in patients with type 2 diabetes the association 
between CNDP1 and DN is sex specific, with a decreased risk in women with the 
5L–5L genotype [13]. In the current study, we found a trend towards different risk of 
mortality between men and women, with a trend toward increased risk in women 
with 5L–5L genotype compared with men. In contrast to these findings, however, 
our study did not indicate an interaction by sex for the prospective relation of 5L–
5L genotype with ESRD. Furthermore, a protective role of 5L–5L for progression to 
ESRD in patients with DN could not be confirmed in our large study nor in a previous 
study in type 1 diabetes [23]. Differences in factors or genes predisposing for DN or 
mortality between type 1 and type 2 diabetes may underlie discrepant findings of 
cross-sectional analyses of associations of 5L–5L with DN in patients with type 1 and 
type 2 diabetes [29].
Although CNDP1 polymorphism was not associated with DN in our population, it 
should be noted that once DN is established, the 5L–5L genotype appeared to be 
significantly associated with increased rather than decreased risk of progression 
to ESRD beyond 6 years of follow-up. A possible explanation for this discrepancy 
from previous findings that suggested a protective role of 5L–5L could be that other 
unidentified risk alleles may be involved in deterioration of renal function in diabetic 
patients. For example, McDonough et al. [30] have shown that in African-Americans, 
a population in which there is no association of CNDP1 and CNDP2 with ESRD, other 
variants in this region of chromosome 18 are contributing to risk of DN. These other 
variants may mask or modify the effect of 5L–5L. Another potential explanation for an 
inverse association between CNDP1 and ESRD to only appear after prolonged follow-
up could lie in environmental factors that alter over time, such as glycaemic control. 
Indeed, Riedl et al. [31] have shown that hyperglycaemia enhances secretion of 
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role in susceptibility to DN and ESRD. Whether 5L–5L genotype also determines the 
consequent availability of the intracellular precursor of carnosinase and whether 
this may have consequences for intracellular carnosine concentrations remains to 
be investigated.
The strength of our study is its prospective design. It was also performed in three 
independent, but relatively homogeneous, populations of white patients with type 1 
diabetes mellitus, and it included more cases and controls than all previous studies 
on the CNDP1 polymorphism.
In conclusion, this study provides evidence that CNDP1 polymorphism is neither 
related to risk for mortality nor interacts with DN regarding survival in white Europeans 
with type 1 diabetes. Homozygosity for the 5-leucine repeat was associated with 
increased risk of progression from nephropathy to ESRD after prolonged follow-
up. Based on these results, we suggest that possible interaction between CNDP1 
polymorphism and other candidate genes or environmental factors in different 
populations should be further investigated, preferably in prospective studies, in 
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Sex specific association between carnosinase gene 
(CNDP1) and cardiovascular mortality in patients 
with type 2 diabetes
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Homozygosity for a 5-leucine repeat (5L-5L) in the carnosinase gene (CNDP1) has 
been found to be associated with a reduced prevalence of diabetic nephropathy in 
cross-sectional studies in type 2 diabetes, particularly in women. Data on mortality 
are not available. We prospectively investigated whether 5L-5L is associated with 
mortality or progression of renal function loss and to what extent this effect is 
modified by sex.
Methods
Prospective study in patients with type 2 diabetes. A Cox proportional hazard 
model was used to compare 5L-5L with other genotypes regarding (cardiovascular) 
mortality. Renal function slopes were obtained by within-individual linear regression 
of the estimated glomerular filtration rate (eGFR) using Modification of Diet in Renal 
Disease equation (MDRD) and compared between 5L-5L and other genotypes.
Results
871 patients were included (330 (38%) with 5L-5L). After 9.5 years of follow-up, 
hazards ratios (HR) for all-cause and cardiovascular mortality in 5L-5L versus other 
genotypes were 1.09 (95%CI 0.88-1.36) and 1.12 (95%CI 0.79-1.58), respectively. 
After adjustment for relevant confounders, there was a significant interaction 
between CNDP1 and sex for the association with cardiovascular mortality (P=0.01), 
but not for all-cause mortality (P=0.32). Adjusted HR in 5L-5L for cardiovascular 
mortality was 0.69 (95%CI 0.39-1.23) in males and 1.77 (95%CI 1.12-2.81) in females. 
Regarding slopes of eGFR-MDRD, neither significant difference between 5L-5L and 
other genotypes nor interaction between CNDP1 and sex was found.
Conclusions
The association between CNDP1 and cardiovascular mortality was sex-specific, with 








































The epidemic of type 2 diabetes is associated with an increasing number of patients 
with micro- and macrovascular complications, leading to substantial mortality. In 
addition to traditional cardiovascular risk factors, such as hypertension and smoking, 
genetic predisposition has been suggested to play a role in susceptibility for diabetic 
complications, including diabetic nephropathy (DN) [1, 2].
Recently, a locus on chromosome 18q, which contains two carnosinase dipeptidase 
genes (CNDP1 and CNDP2), was found to be associated with DN [3, 4]. CNDP1 
encodes the enzyme serum carnosinase which hydrolyses and breaks down histidine-
containing dipeptides such as L-carnosine while CNDP2 encodes a non-specific 
dipeptidase [5]. The addition of L-carnosine to human podocytes and mesangial cells 
in vitro blocked glucose-induced, TGF-dependent extracellular matrix production in 
these cells, suggesting a protective role of carnosine against diabetic complications 
[6]. Interestingly, genetic variation in CNDP1, determined by a trinucleotide repeat 
polymorphism (D18S880, coding for five to seven leucine repeats), was correlated 
with serum carnosinase activity in healthy volunteers [7, 8]. Moreover, homozygosity 
for 5 leucine repeats (5L-5L) encodes for the lowest serum carnosinase activity in 
patients with type 2 diabetes [7]. Several cross-sectional studies have shown the 
frequency of 5L-5L genotype to be higher in patients without DN compared to those 
with DN, suggesting a protective effect of 5L-5L genotype on DN [7-9]. A recent cross 
sectional study in patients with type 2 diabetes has suggested the correlation between 
CNDP1 and DN to be sex-specific, with protection by the 5L-5L homozygous genotype 
restricted to women [10]. It was assumed that this could be attributed to that fact 
that men have higher carnosine levels in their muscle tissue and women have slightly 
higher serum carnosinase levels [11], and that differences in carnosinase activity due 
to the different CNDP1 polymorphism may have a stronger impact in women.
Although many cross-sectional studies suggested CNDP1 polymorphism as a 
protective factor against DN, longitudinal studies in patients with type 2 diabetes on 
CNDP1 polymorphism (leucine repeat polymorphism D18S880) and its relationship 





































Therefore, we aimed to investigate in a prospectively designed cohort study of patients 
with type 2 diabetes, whether CNDP1 is associated with the risk of (cardiovascular) 




In 1998, a large shared-care diabetes project was initiated: the Zwolle Outpatient 
Diabetes project Integrating Available Care (ZODIAC) [12]. In brief, hospital-based 
specialist diabetes nurses assist general practitioners in caring for patients with type 
2 diabetes. Of all the patients in primary care in the Zwolle region, 90% participated in 
this study and 10% were excluded or refused to participate. Nearly all patients (99%) 
are Caucasian. Patients with a very short life expectancy or with insufficient cognitive 
abilities were excluded, as well as patients being treated by an internist. At the end of 
the project’s first year (1998) and the start of the second year (1999), blood was taken 
from 913 consecutive patients and stored for future research. In this prospective 
study, patients were followed until 2009. Life status and cause of death were 
obtained from records maintained by the hospital and general practitioners. Causes 
of death were coded according to the International Classification of Diseases, ninth 
revision (ICD-9). The ZODIAC study was approved by the medical ethics committee of 
the Isala Clinics in Zwolle, the Netherlands, and all patients signed informed consent. 
Baseline clinical laboratory investigations
Baseline data were collected in 1998 and 1999. Physical assessments and laboratory 
measurements were performed annually. HbA1c was determined by standard HPLC 
techniques with normal values in the range 4.1% to 6.4%. The kinetic colorimetric 
Jaffé method [13] was used to measure creatinine in serum and urine (Modular P800 
Analyzer; Roche, Almere, the Netherlands) until march 2007, thereafter an enzymatic 
technique (Modular P Analyzer from Roche, Creatinine Plus assay, Roche Diagnostics, 
Mannheim, Germany) was used. Based on a measured difference between the Jaffé 
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to the plasma creatinine values measured after March 2007 in order to adjust for 
the measured difference in plasma creatinine. Renal function was estimated by 
the 4-variable Modification of Diet in Renal Disease equation (MDRD) [14]. Urinary 
albumin-creatinine ratio (UACR) was measured in spot morning urine samples. 
Blood samples to isolate DNA material were collected at baseline. Genotyping was 
performed as described previously (5). In brief, after PCR amplification, fragment 
analysis was performed on the ABI-3130 analyzer to determine the number of 
trinucleotide repeats of exon 2 in each allele. The success rate was 95%, and no 
errors were detected. Genotyping was performed in Leiden and Mannheim.
Statistical analysis
Variables with normal distribution are presented as mean and standard deviation 
(SD) and variables with skewed distribution are log-transformed before analysis 
and presented as median and interquartile range (IQR). For variables with normal 
distribution, comparisons between groups were performed by using unpaired 
Student’s t-tests, whereas for variables with skewed distribution Mann-Whitney-U 
tests were used. Chi-square tests were used to compare non-continuous variables.
The 5L-5L homozygous genotype was compared to genotypes with six or more 
leucine repeats (i.e. recessive model), in accordance with previous studies [10, 15, 
16]. Time-to-event analyses were performed using Kaplan–Meier plots and log-rank 
testing. Tests for a non-zero slope of scaled Schoenfeld residuals on functions of 
time were performed to explore the proportional hazards (PH) assumption in Cox 
regression models [17]. Cox regression models were used to estimate unadjusted 
and adjusted hazard ratios with 95% confidence intervals (CI) for all-cause mortality 
and cardiovascular mortality. Three models were constructed: The crude model, 
a model after adjustment for age and gender, and a model after adjustment for 
additional confounders, including body mass index, smoking status, duration of 
diabetes, history of macrovascular complications (patients were considered to 
have macrovascular complications when they had a history of angina pectoris, 
myocardial infarction, percutaneous transluminal coronary angioplasty, coronary 
artery bypass grafting, stroke or transient ischemic attack), systolic blood pressure, 





































excretion. Subsequently, in order to investigate whether the correlation between 
CNDP1 polymorphism and mortality was gender-specific, an interaction term (CNDP1 
polymorphism*gender) was used in all models. In case the interaction term was 
significant, stratification according to sex was performed to calculate HR for mortality 
in males and females separately. We also tested for interaction between genotype 
and HbA1c because a recent study suggested that the effect of the genotype on 
plasma carnosinase activity is modified by levels of glycaemia [18]. Following the 
suggestion of Mathew et al. [19], the individual change in eGFR-MDRD during the 
follow-up time was modelled as a linear function of time with an individual slope 
and intercept. For this analysis, patients with at least 3 known values of eGFR-MDRD 
were included. A negative slope function indicates a decrease in eGFR-MDRD over 
time and a positive slope function indicates an increase in eGFR-MDRD over time. 
The bivariate correlations procedure was used to evaluate the correlation between 
the eGFR-MDRD slope functions and different baseline parameters. To compare the 
slopes of 5L-5L carriers with the slopes of patients with other genotypes, the Mann-
whitney U test was used. In order to investigate whether the correlation between 
CNDP1 polymorphism and eGFR-MDRD slopes is gender-specific, general linear 
model (GLM) univariate analysis was used to adjust for baseline variables and to 
build a model with an interaction term (CNDP1 polymorphism*gender).
A two-tailed p-value of 0.05 or less was considered statistically significant. Statistical 
analyses were done by using a commercially available program (SPSS for Windows, 




A total of 913 patients were included in this study. The genotype from 42 patients 
could not be determined due to poor quality DNA. The baseline characteristics of 
these patients were not different compared to the patients with known genotype 
(general linear model (GLM) statistics F= 1.225, P= 0.25 (data not shown)). Table 1 
shows the baseline characteristics of the study population (n = 871) according to 
genotype. 5L-5L was found in 330 patients (38%; for men this was 39%; for women 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Except for slightly lower plasma creatinine and correspondingly higher eGFR in 
patients with 5L-5L, no significant differences at baseline were found between 5L-5L 
and other genotypes.
Follow-up: mortality
After 9.5 (IQ 5.9-10.3) years of follow-up, 136 (41%) patients with 5L-5L and 205 
(38%) patients with other genotypes had died (log-rank test P= 0.39). Regarding 
cardiovascular mortality, these numbers were 55 (17%) and 81 (15%), respectively 
(log-rank test P= 0.51). The PH assumption was met in all Cox regression models (test 
based on Schoenfeld residuals p>0.05). The hazard ratio (HR) for all-cause mortality 
in patients with 5L-5L compared to other genotypes was 1.09 (95% (CI) 0.88-1.36). 
Regarding cardiovascular mortality, the HR was 1.12 (95%CI 0.79-1.58). Adjusted 
hazard ratios for all-cause mortality and cardiovascular mortality are presented 
in table 2. In model 2 (adjusted for age and gender) and model 3 (fully-adjusted 
model), there was a significant interaction between CNDP1 and sex for prediction 
of cardiovascular mortality (P for interaction 0.05 and 0.01, respectively), but not 
for all-cause mortality. After stratification for sex, fully adjusted HRs of 5L-5L for 
cardiovascular mortality were 0.66 (0.37-1.18) in males and 1.81 (95%CI 1.14-2.86) 
in females (table 2 and figure 1). Analyses on interaction between CNDP1 and A1c 
for prediction of all-cause mortality and cardiovascular mortality did not reveal 
































































































































































































































































































































































































































































































































































































































































































































































































































































































                 Adjusted hazard ratio: 0.69 (95%CI 0.39-1.23)
                 Adjusted hazard ratio: 1.77 (95%CI 1.12-2.81)
Figure 1: Adjusted survival curves for cardiovascular mortality in males en females according 
to CNDP1 genotype (5L-5L vs. other genotypes). Solid line, 5L–5L genotype; dotted line, all 
other genotypes
Follow-up: progression of renal function loss
The individual slopes of eGFR-MDRD were calculated in 779 patients (89%). The 
median [IQR] of the slopes was -1.00 [-2.12; -0.08] mL/min/1.73m2/year. As shown 
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correlated with eGFR-MDRD slopes. In patients with 5L-5L genotype, eGFR-MDRD 
slopes were not significantly different from the slopes in patients with other genotypes 
(-1.10 [-2.18; -0.15] vs. -0.95 [-2.07; -0.06], respectively, P = 0.36). Adjustment for 
baseline variables in GLM analysis revealed similar results (data not shown). GLM 
analysis showed no significant interaction between CNDP1 polymorphism and 
gender regarding slopes of eGFR-MDRD (P for interaction 0.99).
Table 3: Pearson correlation coefficients for the correlation between eGFR-MDRD slopes and 
baseline parameters. 





Smoking status 0.01 0.76
Diabetes duration 0.06 0.12
History of macrovascular complications -0.07 0.05
SBP -0.03 0.36
HbA1c -0.04 0.30
Total cholesterol/HDL 0.07 0.03
eGFR-MDRD -0.11 0.001
UAER -0.14 <0.001
CNDP1 polymorphism 0.02 0.58
BMI, body mass index; SBP, systolic blood pressure; A1c, Glycated haemoglobin; HDL, high-
density cholesterol; eGFR-MDRD, estimated glomerular filtration rate using Modification of 
Diet in Renal Disease equation; UAER, urinary albumin excretion rate
dIsCussIon
For the first time in a prospective cohort of patients with type 2 diabetes, we found 
that CNDP1 gene was associated with cardiovascular mortality in a sex-specific 
manner. In female patients, a higher risk for cardiovascular mortality was found in 
carriers of 5L-5L genotype compared to other genotypes. Neither an association nor 
an interaction with gender was found concerning all-cause mortality or progression 
of renal function loss over time. Data from previous cross-sectional studies on CNDP1 





































1 and type 2 diabetes (135 cases and 107 controls), a protective effect of 5L-5L was 
suggested, based on the finding that patients without DN were frequent carriers 
of the 5L-5L genotype, compared to those with other genotypes [7]. In the same 
study, the 5L-5L genotype (CNDP1 variant with the lowest number of leucine repeats) 
was shown to be associated with the lowest serum carnosinase activity compared 
to other genotypes (5L-6L, 6L-6L, 6L-7L, 7L-7L) [7]. This finding was supported by a 
larger cross-sectional study in 552 Caucasian patients (European American) with type 
2 diabetes, that found subjects lacking nephropathy to be more frequently carriers 
of 5L-5L compared to those with diabetes-related ESRD [9]. On the other hand, large 
cross-sectional studies in African Americans [20] and Scandinavians [21] with type 2 
diabetes did not replicate the finding of an association between the polymorphism 
in CNDP1 gene and DN or ESRD. Interestingly, a recent study suggested that the 
association between CNDP1 and DN in type 2 diabetes was limited to women, with 
a lower frequency of 5L-5L in patients with DN compared to those without DN [10].
Based on these findings from cross sectional studies that suggest 5L-5L genotype 
of CNDP1 polymorphism as a protective factor against DN, we aimed to investigate 
whether 5L-5L genotype is associated with risk of (cardiovascular) mortality or 
progression of renal function loss in patients with type 2 diabetes. In this prospective 
study, while no association was found between CNDP1 polymorphism and progression 
of renal function loss, we found a sex-specific association of CNDP1 polymorphism 
and cardiovascular mortality. In our study, women with 5L-5L were at higher risk 
for cardiovascular mortality compared to other genotypes. At present, there is no 
clear explanation for the difference between findings from our prospective study and 
findings from previous cross-sectional studies. Prospective studies in patients with 
type 1 diabetes also failed to confirm findings from cross sectional studies on CNDP1 
gene [15, 16]. Rather, one study found an opposite effect, with increased risk of 
development of end-stage renal disease in patients with 5L-5L beyond a certain time 
of follow-up [16], which is in line with our current finding of 5L-5L being a risk factor 
for cardiovascular mortality in women. The exact cardiac cause of death in women 
with type 2 diabetes and 5L-5L genotype has not been documented. However, a 
previous study has failed to demonstrate a correlation between CNDP1 genotype 
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polymorphism of CNDP1 affects susceptibility to develop diabetic cardiomyopathy 
and not coronary atherosclerosis. To which extent carnosine metabolism in the 
myocard is different from skeletal muscle and the kidney remains to be investigated.
Several factors may underlie the discrepancy between findings from cross-sectional 
and prospective studies. Firstly, if women with 5L-5L truly have an increased risk for 
cardiovascular mortality, many women with 5L-5L and type 2 diabetes could have 
died before being included in cross-sectional analyses, thereby leading to a bias with 
underestimation of the true effect associated with 5L-5L. Our prospective study was 
part of one of the cross-sectional analyses previously performed [10], increasing 
the likelihood of the above mentioned potential explanation. Secondly, other 
polymorphisms in CNDP1 and CNDP2 genes were found to play a role in the risk of DN 
and ESRD [20, 21] and interaction between genotype and glycemic status was found 
to influence the activity of CNDP1 gene [18]. Thus, it is still to be investigated if other 
polymorphisms in CNDP1 and CNDP2, in addition to leucine repeats polymorphism 
in CNDP1, affect serum carnosinase activity. The exact mechanism by which CNDP1 
polymorphism may exert its effects in diabetes is still to be investigated. While 5L-5L 
was found to result in the lowest activity of serum carnosinase and thereby suggested 
to be associated with high levels of serum carnosine [7, 23], intracellular carnosine 
may not necessarily be influenced by CNDP1 polymorphism. For instance, a recent 
study has shown muscle carnosine to be independent of CNDP1 polymorphism [24]. 
Besides, a physiologic effect of leucine repeat polymorphism in CNDP1 on serum 
carnosine has not yet been fully clarified, since serum carnosine levels appeared to be 
undetectable in humans due to the presence of highly active serum carnosinase [25]. 
Strengths of our study are the prospective design, the large number of patients 
and the long duration of follow-up. Limitations are that we did not have data on 
carnosinase activity, which could have given us additional information on the actual 
effect of CNDP1 gene on carnosine metabolism. Besides, caution is warranted when 
interpreting the results of slopes of eGFR-MDRD, taking the limitations of the MDRD 
Study equation into consideration [26]. Long-term estimation of renal function using 
slopes of eGFR-MDRD have been shown to slightly underestimate the renal function 





































that absence of significant association between CNDP1 polymorphism and slopes of 
eGFR-MDRD in this study does not exclude the role of CNDP1 in risk of development 
of DN. Prospective data on albuminuria and use of renin-angiotensin-aldosterone-
system blockade are necessary to investigate this issue.
In conclusion, CNDP1 polymorphism was not associated with all-cause mortality or 
progression of renal function loss in patients with type 2 diabetes. Only in female 
patients, 5L-5L genotype was associated with higher risk of cardiovascular mortality 
compared to those with other genotypes. Further prospective studies that preferably 
measure carnosinase activity are necessary to understand the mechanism by which 
CNDP1 influences carnosine metabolism and vascular complications of diabetes. 
Replication of our findings will increase the probability of the sex-specific association 
found. With the prospective nature of our study, it is more likely that in women with 
type 2 diabetes, 5L-5L genotype is associated with increased cardiovascular mortality 
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Chapter 4
Impact of ACE I/D and CCR2 V64I polymorphisms on 
new-onset microalbuminuria in type 2 diabetes; 
evidence from the BENEDICT trial 
Alkhalaf A, Bakker SJL, Porrini E, Perna A, Valoti E, 








































Beside activation of Renin-angiotensin-aldosterone system (RAAS), monocyte 
chemoattractant protein-1 and its receptor (CCR2) are also suggested to play an 
important role in renal disease, including diabetic nephropathy. We prospectively 
investigated whether genetic variations in ACE gene (ACE I/D polymorphism) predicts 
new-onset microalbuminuria, (2) CCR2 V64I polymorphism has additional value in 
addition to ACE I/D polymorphism, and (3) there is an interaction between either 
of these polymorphisms and treatment with ACE-I for prediction of new-onset 
microalbuminuria.
Methods
ACE I/D and CCR2 V64I was genotyped by agarose gel electrophoresis and sequences 
analysis respectively in 1128 patients from the BErgamo NEphrologic Diabetic 
Complications Trial (BENEDICT) – a prospective randomized trial evaluating ACE 
inhibition effect on new-onset microalbuminuria (albuminuria 20-200 µg/min) in 
hypertensive type 2 diabetes patients without albuminuria (<20 µg/min) at inclusion.
Results
During a median follow-up of 42.3 months, ACE I/D was significantly associated 
with increased new-onset microalbuminuria; unadjusted hazards ratio (HR) for 
microalbuminuria in DD compared to II/ID was 1.56 (95%CI 1.05-2.32, P = 0.03). 
Adjusted HR was 1.21 (95%CI 0.81-1.82, P = 0.35). CCR2 V64I was not significantly 
associated with new-onset microalbuminuria; Unadjusted HR for microalbuminuria 
in VI/II compared to VV was 1.35, 95%CI 0.85-2.14, P = 0.198, adjusted HR was 1.42 
(95%CI 0.89-2.25, P = 0.14). The unadjusted HR for development of microalbuminuria 
in patients with both mutant genotypes, i.e. DD from ACE I/D and VI/II from 
CCR2, compared to carriers of neither of these genotypes, i.e. ID/DD and VV, was 
2.17 (95%CI 1.14-4.13, P=0.02), adjusted HR 1.58 (95%CI 0.82-3.04, P = 0.17). No 
significant interaction was found between ACE-I treatment and ACE I/D or CCR2 V64I.
Conclusions
DD carriers of ACE I/D SNP had significantly increased risk of microalbuminuria 
compared to II/ID carriers, even after adjustment for ACE-I treatment, but not after 
further adjustment for other risk factors. CCR2 V64I did not predict new-onset 
microalbuminuria. Carriers of both “risk” genotypes DD and VI/II have increased risk 
of developing microalbuminuria compared to carriers of both “protective” genotypes, 







































Inhibiting of renin-angiotensin-aldosterone system (RAAS) by use of angiotensin-
converting enzyme inhibitors (ACE-I) and/or angiotensin-receptor blockers (ARB) 
is currently the first-line therapy for prevention and treatment of DN, due to their 
important hemodynamic effects on blood pressure and their antiproteinuric action 
[1-3]. Interestingly, the circulating and renal activity of the RAAS has been shown 
to be influenced by genetic factors, such as an intronic 287 bp Alu repeat sequence 
insertion (I) /deletion (D) polymorphism of the angiotensin-converting enzyme 
(ACE) gene. Subjects with DD genotype of the ACE gene had a worse renal function 
prognosis compared with those carrying the II genotype [4, 5]. In patients with 
diabetes, several studies supported the genetic association of ACE I/D polymorphism 
with DN, as confirmed in a recent meta-analysis [6]. However, prospective data on 
the impact of ACE I/D polymorphism on the incidence of microalbuminuria and the 
possible interaction of ACE I/D with RAAS-blockade to prevent DN are not available.
On the other hand, beyond the various hemodynamic effects of RAAS on glomeruli 
and filtration rate, angiotensin II has been shown to stimulate tubulointerstitial 
inflammation and fibrosis by release of cytokines, growth factors, and chemokines 
that induce recruitment of macrophages and lymphocytes in arterial wall [7, 
8]. The prototype chemokine, monocyte chemoattractant protein-1 (MCP-1), 
which is activated by its C-C chemokine receptor (CCR2), is implicated in chronic 
monocyte-mediated inflammation and endothelial damage [9, 10]. In animal 
experiments, CCR2 inhibition has been shown to protect the kidney in hypertensive 
states by reducing inflammation and delaying the progression of hypertension 
[11]. A single nucleotide polymorphism (SNP) causing replacement of valine 
by isoleucine at position 64 in the CCR2 gene on chromosome 3 (CCR2-V64I) 
has been reported to play a modulating role in the MCP-1 pathway. CCR2-V64I 
polymorphism, which occurs with an allele frequency of 10-25% depending on 
ethnic populations (NCBI, SNP rs1799864), has been associated with inflammatory 
vascular diseases including myocardial infarction [12], carotid atherosclerosis [13] 
and preeclampsia [14]. Based on this, we hypothesized that genetic variations 





































DN and the response to renoprotective therapies in patients with type 2 diabetes. 
Thus, in a large cohort of hypertensive normoalbuminuric patients with type 
2 diabetes who participated in phase A of the BErgamo NEphrologic Diabetic 
Complications Trial (BENEDICT), we prospectively investigated whether: (1) ACE I/D 
polymorphism predicts new-onset microalbuminuria, (2) CCR2 V64I polymorphism 
synergizes with the ACE I/D polymorphism in determining the risk of DN, and (3) 
there is an interaction between either of these polymorphisms and treatment with 
ACE-I for prevention of new-onset microalbuminuria.
Methods
Patients
BENEDICT was a double-blind, randomized, placebo-controlled and prospective trial 
aimed to assess whether ACE-I and nondehydropyridine calcium-channel blockers, 
alone or in combination, prevent microalbuminuria in subjects with type 2 diabetes, 
hypertension and normal urinary albumin excretion (UAE) at baseline [2]. Patients 
(n=1204) who fulfilled inclusion criteria for the clinical study (age >40 years, type 2 
diabetes duration ≤ 25 years, serum creatinine <1.5 mg/dl, glycated haemoglobin 
A1c <11%, blood pressure higher than 140/90 mmHg after 3 weeks without 
antihypertensive treatment or lower than 140/90 mmHg with antihypertensive 
treatment and urinary albumine excretion<20 μg/min), were randomly allocated 
to at least 3-years treatment with ACE-I trandolapril, nondehydropyridine calcium-
channel blocker verapamil, combination of trandolapril plus verapamil or placebo 
[2]. Primary endpoint was new-onset persistent microalbuminuria (UAE ≥20 µg/min 
and <200 µg/min in at least two of three consecutive onvernight urine collections 
on two consecutive visits 2 months apart). UAE was measured on fresh urine at the 
coordinating centre by nephelometry (Beckman Array System; Beckman Coulter) at 
randomization and every 6 months thereafter.
Trandolapril plus verapamil and trandolapril alone significantly delayed the onset 
of microalbuminuria by factors of 2.6 and 2.1, respectively, compared with placebo 
(P < 0.01 for both). The incidence of microalbuminuria was reduced to a similar 
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microalbuminuria that was similar to that of placebo [2]. Thus, patients were pooled 
in two cohorts according to their original allocation to ACE or non-ACE inhibitor 
therapy regardless of concomitant therapy with verapamil or placebo. Gene by 
treatment interactions were tested according to ACE inhibitor therapy (yes or no).
The study protocol was approved by the local ethics committees, and only samples 
from patients who provided written informed consents according to the Helsinki 
Declaration guidelines were considered for genetic analyses. All data were handled 
in respect of patient confidentiality and anonymity.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes by standard methods. 
Genotyping for ACE I/D polymorphism was determined according to the method 
described by Rigat et al. [15] while the CCR2 V64I polymorphism (CCR2 G190A), 
coding Val64Ile, was performed using direct sequencing analysis. Genotyping success 
rate was >99%. As a quality-control procedure, we doubled genotyped for ACEI/D a 
subset of 200 individuals by direct sequencing. The concordance rate between the 
two genotyping methods was 100%.
Statistical analysis 
Variables with normal distribution are presented as mean ± standard deviation 
(SD) and variables with skewed distribution were log-transformed before analysis 
and presented as median and interquartile range (IQR). For variables with normal 
distribution, comparisons between groups were performed by using unpaired 
Student’s t-tests, whereas for variables with skewed distribution Mann-Whitney-U 
tests were used. χ2-tests were used to compare non-continuous variables. Time to 
onset of microalbuminuria was considered as the main endpoint. For patients who 
did not reach the main endpoint, time was censored for the last follow-up visit. 
Analyses of time to main endpoint were performed using Kaplan-Meier plots and log-
rank testing. Cox regression models were used to estimate unadjusted and adjusted 
hazard ratios (HR) with 95% confidence interval (CI). To test the difference between 
different genotypes on outcome, four statistical models were constructed: the first 





































third is a model further adjusted for baseline urinary albumin excretion rate and 
the fourth model is further adjusted for other potential confounders which were 
a priori defined: age, sex, smoking status duration of diabetes, baseline glycated 
haemoglobin (A1c) and baseline systolic blood pressure. For assessment of response 
to treatment with ACE-I according to genotype, two models were used: a crude 
model and a model after adjustment for potential confounders. To test whether 
there is an interaction between genotype (ACE I/D or CCR2 V64I) or treatment with 
ACE-I, an interaction term (genotype*treatment) was used in the Cox-regression 
model. Besides, incidences of new-onset microalbuminuria in each subgroup were 
calculated and compared with each other by Pearson χ2-tests. A two-tailed P-value of 
0.05 or less was considered statistically significant. Statistical analyses were done by 




Of the 1,204 BENEDICT patients, genomic DNA was available from 1128 patients. 
Baseline characteristics of those from whom no genotype is known (n=76) were not 
significantly different from those who were genotyped. Of the 1128 patients, 429 
(38%) were homozygous for the D allele of the ACE gene, from now DD carriers, 
while 526 (46.6%) and 173 (15.3%) were heterozygous and homozygous for the I 
allele, respectively, from now on II/ID carriers (figure 1). Genotype frequencies for 
the ACE gene are in Hardy-Weinberg equilibrium (χ2= 0.3, FD=1, P=0.58). Regarding 
CCR2 gene, 226 patients (20%) were homozygous or heterozygous carriers of the 64I 
variant, from now on VI/II carriers, and 902 patients (80%) were homozygous for the 
V allele (VV) of CCR2 gene, from now on VV carriers. (figure 1). Genotype frequencies 
for the CCR2 gene are also in Hardy-Weinberg equilibrium (χ2= 2.63, FD=1, P=0.10). 
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Outcome according to ACE I/D genotype
During a follow-up of 42.3 (12.1-51.9) months, 46 out of 429 patients (10.7%) with DD 
developed microalbuminuria versus 52 out of 699 patients (7.4%) with II/ID (log rank 
test P = 0.03, figure 2A). As shown in table 2, DD carriers had significantly increased 
risk of microalbuminuria compared to II/ID carriers, even after adjustment for ACE-I 
treatment, but not after further adjustment for other risk factors.
Response to ACE-I according to ACE I/D genotype
Treatment with ACE-I significantly reduced the incidence of microalbuminuria 
compared with placebo with a reduction of incidence by factors 2.6 and 2.1 for 
treatment with ACE-I plus verapamil and ACE-I alone, respectively, (P < 0.01 for 
both) [2]. Among DD carriers, 16 of the 208 patients (7.7%) on ACE-I and 30 of the 
221 patients (13.58 %) that did not receive ACE-I developed microalbuminuria; log 
rank test P= 0.038. Similarly, in II/ID carriers incidence of microalbuminuria was 
significantly lower in those on ACE (17/353, 4.8%) compared to those on non-ACE 
inhibitor therapy (35/346, 10.1%); log rank test P= 0.002. As shown in table 3, ACE-I 
significantly protected from development of microalbuminuria in both DD and II/ID 
genotype carriers. No significant interaction was found between ACE-I treatment and 
ACE I/D (P for treatment*genotype 0.54).
Outcome according to CCR2V64I genotype 
Among VI/II carriers, 24 out of 226 patients (10.6%) developed microalbuminuria 
versus 74 out of 902 patients (8.2%) with the VV genotype (log rank test P= 0.21, 
figure 2B). As shown in table 2, incidence of microalbuminuria was not significantly 
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log rank test P = 0.0384 86 Log rank test P = 0.19
82 84
Patients at risk Time days
0 500 1000 1500 2000 0 500 1000 1500 2000
Time daysPatients at risk
ID+II 699 524 459 222 93 VI+II 226 154 133 63 22
DD 429 315 264 120 45 VV 902 641 559 262 110
C:  DD/ VI+II vs (II+VV and ID+VV)








































































































































log rank test P = 0.0384 86 Log rank test P = 0.19
82 84
Patients at risk Time days
0 500 1000 1500 2000 0 500 1000 1500 2000
Time daysPatients at risk
ID+II 699 524 459 222 93 VI+II 226 154 133 63 22
DD 429 315 264 120 45 VV 902 641 559 262 110
C:  DD/ VI+II vs (II+VV and ID+VV)Figure 2: Kaplan–Meier curves of albuminuria in patients with type 2 diabetes according to A: 
ACE I/D and B: CCR2 V64I genotypes
Response to ACE-I according to CCR2 V64I genotype 
Among VI/II carriers, 6 of the 112 patients (5.4%) on ACE-I and 18 of the 114 patients 
(15.8%) that did not receive ACE-I developed microalbuminuria; log rank test 
P= 0.013. Similarly in VV carriers, incidence of microalbuminuria was significantly 





































47/453, 10.4%, respectively); log rank test P= 0.04. As shown in table 3, ACE-I 
significantly protected from development of microalbuminuria in both VV and VI/
II genotype carriers. Althoughthe Mantel-Haenszel chisquared test confirmed the 
different ACE-1 effect in the 2 genotype groups (Chi-square MH = 11.05, df = 1 and 
p-value = 0.0009), no significant interaction was found between ACE-I treatment and 
CCR2 V64I (P for interaction term treatment * genotype 0.37)
Outcome according to combined genotypes ACE I/D and CCR2 V64I
The risk for developing microalbuminuria progressively increased moving from 
carriers of protective genotypes for both ACE and CCR2 genes (i.e., II/ID and VV) to 
carriers of either CCR2 (VI/II and II/ID) or ACE (DD and VV) “risk” genotypes alone to 
carriers of both risk genotypes (DD and VI/II). As shown in table 2, the unadjusted HR 
for development of microalbuminuria in patients with both “risk” genotypic variants, 
i.e. DD from ACE I/D and VI/II from CCR2, compared to carriers of neither of these 
genotypes, i.e. ID/II and VV, was 2.17 (95%CI 1.14-4.13, P=0.02). This increased risk 
of microalbuminuria in carriers of both DD and VI/II was significant after adjustment 
for ACE-I, but not after further adjustment for other risk factors (table 2).
Response to ACE-I according to combined ACE I/D and CCR2 V64I genotypes
As shown in table 3 and table 4, among carriers of “risk” genotypes for both ACE 
and CCR2 genes (i.e., DD and VI/II), treatment with ACE-I did not significantly protect 
from microalbuminuria. Of notethere was a trend toward protective effect of ACE-I 
in carriers of both II/ID and VV, while the highest efficacy of ACE-I was observed in 
carriers of VI/II plus ID/II genotypes (table 4). No significant interaction was found 
between ACE-I treatment and combined genotypes (ACE I/D and CCR2 V64I) (P for 

















































































































































































































































































































































































































































































































































Table 4: Effect of ACE-I on incidence of microalbuminuria according to genotype
Genotype n
Incidence of 








DD + VI/II 86 16.28 11.63 0.63 4.65 29
II/ID + VV 559 8.73 5.63 0.06 3.10 36
DD + VV 343 12.92 6.67 0.04 6.25 48
II/ID + VI/II 140 15.5 1.45 0.003 14.05 91
OVERALL 1128 11.46 5.88 <0.001 5.58 49
 
dIsCussIon
In this prospective study we found that ACE I/D polymorphism predicts new-onset 
microalbuminuria in patients with type 2 diabetes. The incidence of microalbuminuria 
was found to be higher in carriers of the deletion allele (DD carriers) compared to 
II/ID carriers. We also prospectively investigated the possible impact of CCR2 V64I 
polymorphism on incidence of microalbuminuria. Although we found that the CCR2 
V64I alone did not significantly predict new-onset microalbuminuria, combined 
analyses of ACE I/D and CCR2 V64I revealed increased risk of reaching the endpoint 
microalbuminuria in carriers of both the “risk genotypes” DD and VI/II compared to 
carriers of both the “protective genotypes” II/ID and VV (figure 3).
Regarding response to therapy, all patients appeared to benefit from ACE-I treatment 
in terms of new-onset microalbuminuria, with lack of interaction between ACE I/D 
and CCR2 V64I on one hand, and treatment with ACE-I on the other hand. Of note, 
combined analysis of both polymorphism showed carriers of both II/ID and VI/II to 
benefit the most from ACE-I treatment with 91% reduction of risk.
This is the first study that examines the potential impact of ACE I/D polymorphism 
on new-onset microalbuminuria in patients with diabetes. Genotypes of ACE I/D 
polymorphism have been evaluated in many studies in diabetic and nondiabetic 
nephropathies. In the REIN study [16], ACE/ID polymorphism did not predict 
progression in GFR or risk of ESRD in 352 patients with nondiabetic proteinuric 
chronic nephropathy. In the same trial, ACE-I treatment is renoprotective in women 
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ACE I/D genotypes and response to treatment was evidenced in male patients, 
indeed ACE-I protected from renal disease progression male patients with the DD 





























Figure 3: Hazard ratio for each genotype.
ACE I/D: II/ID vs. DD
CCR2 V64I: VV vs. VI/II
Combined analysis: II/ID and VV vs. DD and VI/II
The impact of ACE I/D polymorphism on renal outcome in diabetes has been 
investigated in the RENAAL study [18]. In this randomized, double-blind, placebo-
controlled study in 1443 patients with type 2 diabetes and nephropathy, homozygous 
carriers of the D allele had the worse prognosis regarding the composite endpoint of 
doubling serum creatinine, ESRD, and death. Furthermore, treatment with Losartan 
gave the greatest benefit in carriers of the D allele.
In our study, we found that patients with diabetes who were homozygous carriers 
of D allele have increased risk of developing microalbuminuria. However in contrast 
to findings from the RENAAL study, we found that treatment with ACE-I trandolapril 
was uniformly renoprotective in all subgroups of the BENEDICT study, regardless of 





































This discrepancy could be explained by differences in the stage of nephropathy 
at initiation of treatment. In the RENAAL study [18], patients had advanced stage 
of diabetic nephropathy (median urinary albumin/creatinine ratio 1166 mg/g) at 
randomisation, whereas the BENEDICT trial investigated the effect of RAAS blockade 
given as prophylactic intervention in diabetic patients without albuminuria at 
baseline. It could therefore be possible that potential impact of the D allele is more 
pronounced in advanced stages of nephropathy. In situations of overt nephropathy 
and macroalbuminuria, blockade of RAAS is expected to give additional benefit in DD 
carriers who have higher levels of ACE [19] 
Interestingly, this harmful impact of D allele in our study remained significant 
after adjustment for use of ACE-I, but not after adjustment for other risk factors of 
microalbuminuria in the multivariate model. This could be explained by the fact that 
these risk factors are part of the causal pathway between the genetic risk and the 
clinical outcome.
Furthermore, in this study we evaluated the impact of CCR2 V64I polymorphism on 
new-onset microalbuminuria in diabetic patients. CCR2 is a seven-transmembrane, 
protein-coupled receptor of MCP-1, which plays an important role in the 
pathophysiology of renal damage in diabetes by recruitment of monocytes and 
other inflammatory cells [20, 21]. MCP-1 inhibition has been shown to prevent 
glomerulosclerosis and improve glomerular filtration rate in experimental diabetes 
[22]. Recently, Kang et al. [23] have shown that treatment with a CCR2-antagonist 
in diabetic mice resulted in decrease of albuminuria and improvement in mesangial 
expansion by suppression of synthesis of pro-inflammatory molecules in renal 
tissues, including TGF-β1 and type IV collagen. In our study, CCR2 V64I polymorphism 
alone did not predict new-onset microalbuminuria, however combined analyses of 
CCR2 V64I and ACE I/D showed that carriers of VI/II variants from CCR2 V64I who 
also had the DD genotype of ACE I/D were at increased risk of developing new-onset 
microalbuminuria. While this finding could suggest some impact of genetic variation 
in CCR2 in subjects with activated RAAS, our data should be interpreted with caution, 
since the increased risk of microalbuminuria in carriers of the combined DD and VI/
II genotypes was not significant after adjustment for baseline microalbuminuria and 
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In conclusion, ACE I/D polymorphism predicts new-onset microalbuminuria in 
patients with type 2 diabetes without nephropathy, with an increased incidence 
of microalbuminuria inDD carrierscompared to II/ID carriers. Carriers of both 
“risk” genotypes DD and VI/II have increased risk of developing microalbuminuria 
compared to carriers of both “protective” genotypes. Large prospective clinical 
studies are needed to investigate the potential role of CCR2 V64I gene variant in 
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Chapter 5
Multicentric validation of proteomic biomarkers in 
urine specific for diabetic nephropathy 
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Medek K, Mischak H, Roob JM, Rossing K, Rossing P, Rychlík I, Sourij H, Tiran B, 
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Urine proteome analysis is rapidly emerging as a tool for diagnosis and prognosis in 
disease states. For diagnosis of diabetic nephropathy (DN), urinary proteome analysis 
was successfully applied in a pilot study. The validity of the previously established 
proteomic biomarkers with respect to the diagnostic and prognostic potential was 
assessed on a separate set of patients recruited at three different European centers. 
In this case-control study of 148 Caucasian patients with diabetes mellitus type 2 and 
duration ≥5 years, cases of DN were defined as albuminuria >300 mg/d and diabetic 
retinopathy (n=66). Controls were matched for gender and diabetes duration (n=82). 
Methods
Proteome analysis was performed blinded using high-resolution capillary 
electrophoresis coupled with mass spectrometry (CE-MS). Data were evaluated 
employing the previously developed model for DN. 
Results
Upon unblinding, the model for DN showed 93.8% sensitivity and 91.4% specificity, 
with an AUC of 0.948 (95% CI 0.898-0.978). Of 65 previously identified peptides, 
60 were significantly different between cases and controls of this study. In <10% of 
cases and controls classification by proteome analysis not entirely resulted in the 
expected clinical outcome. Analysis of patient’s subsequent clinical course revealed 
later progression to DN in some of the false positive classified DN control patients.
Conclusions
These data provide the first independent confirmation that profiling of the urinary 
proteome by CE-MS can adequately identify subjects with DN, supporting the 
generalizability of this approach. The data further establish urinary collagen fragments 
as biomarkers for diabetes-induced renal damage that may serve as earlier and more 







































Diabetic nephropathy (DN) is a leading cause of morbidity and mortality in patients 
with diabetes mellitus [1]. Accurate diagnostic tools are important, not only for the 
allocation of preventive measures but also to better unravel the complex pathogenesis 
of DN. Current clinical biomarkers used to diagnose diabetic kidney disease, urinary 
albumin excretion and glomerular filtration rate, are subject to considerable 
measurement variability [2], and are heterogeneous as to prognostic impact [3]. 
Whereas albuminuria is broadly used as a renal biomarker, its specificity is still subject 
of debate [4]. Moreover, urinary albumin excretion and glomerular filtration rate 
(GFR) are also affected in non-diabetic renal disease, and accordingly not specific for 
diabetic nephropathy [5]. As such their potential to detect and monitor the specific 
pathogenetic processes involved in diabetic nephropathy is limited. Furthermore, 
especially GFR, but also albuminuria are late stage biomarkers, only indicative after 
substantial organ damage [6]. Alternative non-invasive diagnostic methods, that may 
enable detection of DN at an earlier stage, and/or with higher accuracy, would be 
beneficial for clinical management of diabetic patients, as well as for pathogenetic 
studies aimed at further deciphering pathophysiology, and identifying targets for 
intervention. Potential sources for such biomarkers may be urinary proteins and/
or peptides, as these should display significant changes at an early state of disease, 
displaying initial pathophysiological changes in the kidney [7].
Proteome analysis using capillary electrophoresis coupled mass spectrometry (CE-MS) 
has recently emerged as a powerful tool to define biomarkers that enable diagnosis 
[8, 9], prognosis [10], assessment of therapeutic intervention [11], and monitoring 
of specific pathogenetic pathways. The different technological considerations, both 
with respect to samples and technological platform have recently been discussed 
and reviewed [12-15]. We have focused on urinary proteome analysis as the urinary 
proteome has been found to be quite stable [16, 17] and contains an array of low 
molecular weight proteins and peptides that can be analyzed without the need for 
additional manipulation such as proteolytic digests [18].
Recent studies demonstrated that urinary proteome analysis enables the definition 





































These might prove valuable in clinical practice. As a first step, however, confirmation 
of the diagnostic value of these markers in a controlled study in independent clinical 
centers, different from the ones that were involved in the identification of the 
biomarkers, has to be obtained. Such rigid independent confirmation is required 
prior to any further development, investigating e.g. prognostic value, to clearly 
support the validity and reliability of the biomarkers and biomarker-based models 
[21]. In the past, confirmation of potential disease-associated biomarkers has often 
failed (e.g. [22, 23]), hence this step is of the outmost importance. Therefore, we 
aimed to validate identified biomarkers and a biomarker-based model for DN that 
was described previously in an independent blinded set of samples [1], collected 
prospectively in multiple centers not involved in the original identification of 
biomarkers to rule out any center-based bias.
To ease data interpretation, a case-control set-up was chosen. The low molecular 
proteome of diabetes mellitus type 2 patients with normoalbuminuria (controls) 
and matched diabetes patients with diabetic nephropathy (cases) was analyzed in a 
blinded study (PREDICTIONS study) by capillary electrophoresis-mass spectrometry 




The study was conducted according to the requirements of the Declaration of 
Helsinki, the protocol was approved by the respective Ethical review boards of the 
participating centers (Medical Ethics Committees of the Isala Clinics in Zwolle and of 
the University Medical Center in Groningen, the Ethics Committee of Third Faculty 
of Medicine, Charles University at Prague, and the Ethics Committee of the Medical 
University of Graz), and written informed consent was obtained from all patients.
Settings and participants
The study was set up as a cross-sectional case-control study, cases being type 2 
diabetes patients with nephropathy, controls being type 2 diabetes patients without 
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diabetes of >5 years were eligible. Diagnosis of diabetes was established in accordance 
with the WHO criteria, by the following: fasting plasma glucose >7.0 mmol/l, a two-
hour value in an oral glucose tolerance test >11.1 mmol/l, or random plasma glucose 
>11.1 mmol/l in the presence of symptoms. Type 2 diabetes was diagnosed by lack 
of criteria for type 1 diabetes. Inclusion criteria for cases were: albuminuria >300 
mg/d and known overt diabetic retinopathy. Retinopathy is requested to be present 
is to ensure that albuminuria is the consequence of diabetic nephropathy rather 
than a non-diabetic glomerulopathy. A renal biopsy would be the gold standard to 
discriminate between diabetic nephropathy and a non-diabetic glomerulopathy, but 
a renal biopsy is nearly never taken in diabetic patients and several studies have 
indicated that the request for retinopathy being present is a good alternative for 
discrimination between diabetic nephropathy and non-diabetic glomerulopathy in 
type 2 diabetic patients with albuminuria [24-26]. Exclusion criteria were end stage 
renal failure, known causes of renal failure other than diabetes and non-Caucasian 
ethnic origin. Controls were matched within center for gender and diabetes duration. 
Exclusion criteria for controls were micro-albuminuria, non-Caucausian ethnic origin, 
and in case of use of RAAS-blocking medication, unknown albuminuria status prior to 
start of treatment. Patients were prospectively recruited from the outpatient clinics 
for diabetes and nephrology in three participating centers, located in Zwolle (The 
Netherlands), Graz (Austria), and Prague (Czech Republic), respectively. 
Sample collection and preparation
The second urine of the morning was collected as described [27] and stored frozen 
below -20°C. A 0.7 mL aliquot was thawed immediately before use and diluted with 0.7 
mL 2 M urea, 10 mM NH
4
OH containing 0.02 % SDS. In order to remove high molecular 
weight polypeptides, samples were filtered using Centrisart ultracentrifugation filter 
devices (20 kDa molecular weight cut-off; Sartorius, Goettingen, Germany) at 3,000 g 
until 1.1 mL of filtrate was obtained. Subsequently, filtrate was desalted using PD-10 
column (GE Healthcare, Sweden) equilibrated in 0.01% NH
4
OH in HPLC-grade water. 
Finally, samples were lyophilized and stored at 4°C. Shortly before CE-MS analysis, 
lyophilisates were resuspended in HPLC-grade water to a final protein concentration 






































CE-MS analysis was performed as described [27], using a P/ACE MDQ capillary 
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line coupled to a 
Micro-TOF MS (Bruker Daltonic, Bremen, Germany). Data acquisition and MS 
acquisition methods were automatically controlled by the CE via contact-close-
relays. Spectra were accumulated every 3 s, over a range of m/z 350 to 3000 Th. 
Accuracy, precision, selectivity, sensitivity, reproducibility, and stability are described 
in detail elsewhere [27, 28]. The average recovery of sample in the preparation 
procedure was ~85% and the limit of detection was ~1 fmol. Mass resolution was 
above 8,000 enabling resolution of monoisotopic mass signals for z≤6. After charge 
deconvolution, mass accuracy was <25 ppm for monoisotopic resolution and <100 
ppm for unresolved peaks (z>6). The analytical precision of the set-up was assessed 
by (a) reproducibility achieved for repeated measurement of the same replicate and 
(b) by the reproducibility achieved for repeated preparation and measurement of the 
same urine sample. To ensure high data consistency, a minimum of 950 peptides/
proteins had to be detected with a minimal MS resolution of 8,000 in a minimal 
migration time interval of 10 minutes.
Data processing
Mass spectral ion peaks representing identical molecules at different charge states 
were deconvoluted into single masses using MosaiquesVisu software [29]. Both CE-
migration time and ion signal intensity (amplitude) show variability, mostly due to 
different amounts of salt and peptides in the sample and are consequently normalized. 
Reference signals of 1770 urinary polypeptides are used for CE-time calibration by 
local regression. For normalization of analytical and urine dilution variances, MS 
signal intensities are normalized relative to 29 “housekeeping” peptides generally 
present in at least 90% of all urine samples with small relative standard deviation, 
as described in detail recently [28]. For calibration, local regression is performed. 
The obtained peak lists characterize each polypeptide by its molecular mass [Da], 
normalized CE migration time [min] and normalized signal intensity. All detected 
peptides were deposited, matched, and annotated in a Microsoft SQL database 
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Classification model of DN
Data of the current samples were tested against the previously developed biomarker 
model for DN [1]. Rossing et al. defined and validated models for the differentiation 
of diabetic patients type 1 with macroalbuminuria and normoalbuminuria after 
CE-MS analysis. Among these diabetes patients, 102 urinary biomarkers differed 
significantly between patients with normoalbuminuria and DN. For reduction of the 
number of variables, a “take-one-out” procedure was used, decreasing the number 
of biomarkers to 65 without losing performance in the classification. A support vector 
machine (SVM) biomarker model with these 65 polypeptides identified patients 
with DN in blinded data set of 70 individuals (35 cases and 35 controls) with 100% 
sensitivity and 97% specificity (AUC=0.994). 
SVM-based classification on the urinary peptidome was performed using MosaCluster 
software (version 1.7.0) [30]. This software tool allows the classification of samples 
in the high-dimensional parameter space by using support vector machine (SVM) 
learning. For this purpose, MosaCluster generates polypeptide models, which rely 
on polypeptides displaying statistically significant differences when comparing data 
from patients with a specific disease to controls or other diseases, respectively. 
Each of these polypeptides represents one dimension in the n-dimensional 
parameter space [9, 31-33]. SVM views a data point (probands plasma sample) as 
a p-dimensional vector (p numbers of protein used), and it attempts to separate 
them with a (p-1) dimensional hyperplane. There are many hyperplanes that might 
classify the data. However, maximum separation (margin) between the two classes 
is of additional interest, and therefore, the hyperplane with the maximal distance 
from the hyperplane to the nearest data point is selected. All marker proteins are 
used without any weighting to build up the n-dimensional classification space and 
to display the data set in the classification space. Classification is performed by 
determining the Euclidian distance of the data set to the n-1 dimensional maximal 
margin hyperplane (absolute value of the normal vector) and the direction of the 






































Sensitivity and specificity of the previously defined biomarker models, and 95% 
confidence intervals (95% CI) were calculated using receiver operating characteristic 
(ROC) plots (MedCalc version 8.1.1.0, MedCalc Software, Belgium, www.medcalc.be) 
[34]. Furthermore, Mann-Whitney test (for independent samples) was performed 
to receive Box-Whisker-Plots with this software. Statistical significance was assumed 
at p<0.05. For analysis of differences of individual peaks between cases and 
controls, statistical significance was assumed at p<0.001 to account for multiple 
testing. For the correlation analysis of each peptide biomarker, Rank correlation 
was used with Spearman’s rank correlation coefficient (Spearman’s ρ) (MedCalc 
version 8.1.1.0, MedCalc Software, Belgium, www.medcalc.be). For biomarker 
definition, polypeptides that were found in more than 70 % of the samples in at 
least one of the two groups (DN or non-DN) were considered. This pre-defined set of 
polypeptides was further validated by randomly excluding 30 % of available samples. 
This bootstrapping procedure was repeated up to 10 times. Further on, mutilvariate 
statistic methods (e.g., Benjamini-Hochberg) were applied for selection refinement.
Sequencing of peptides
Candidate biomarkers from urine were sequenced using CE-MS/MS or LC-MS/MS as 
recently described [35].
Raw data files were either converted into dta-files (RAW files generated by ion 
traps from Thermo Fisher Scientific) with the use of DTA Generator [36, 37] or 
into mgf-files (data derived from MALDI-TOF and Q-TOF analyses) with the use of 
DataAnalysis (version 4.0; Bruker Daltonik). All resultant MS/MS data were submitted 
to MASCOT (www.matrixscience.com; release number: 2.3.01) for a search against 
human entries (20,295 sequences) in the Swiss-Prot database (Swiss-Prot number 
2010.06) without any enzyme specificity and with up to one missed cleavage. No 
fixed modification was selected, and oxidation products of methionine, proline, 
and lysine residues were set as variable modifications. Accepted parent ion mass 
deviation was 0.5 Da (20 ppm for all Orbitrap spectra); accepted fragment ion mass 
deviation was 0.7 Da. Only search results with a MASCOT peptide score equally or 
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controlled to be related to main spectral fragment features (b/y or c/z ion series). For 
further validation of obtained peptide identifications, the strict correlation between 
peptide charge at pH 2 and CE-migration time was utilized to minimize false-positive 
identification rates [38, 39]. As depicted in figure 1, the polypeptides are arranged 
in four to five lines. The members of each line are characterized by the numbers 
of basic amino acids (arginine; histidine; lysine) included in the peptide sequence. 
Specifically, the peptides in the right line contain no basic amino acids, only the 
N-terminus of the peptide is positively charged at pH 2. In contrast, peptides in 
the other lines (from right to left) show increasing number of basic amino acids in 
addition to their N-terminal ammonium group [39]. Calculated CE-migration time 
of the sequence candidate based on its peptide sequence (number of basic amino 
acids) was compared to the experimental migration time. A peptide was accepted 
only if it had a mass deviation below ±50 ppm and a CE-migration time deviations 








































Figure 1: Polypeptide patterns of exemplarily urine samples.
The upper panel shows polypeptide patterns of all peptides, which are in the urinary proteome 
from one patient with (ID: 37908) and one patient without DN (ID: 37907). The lower panel 
shows distinct peptides of the DN model of these patients urine sample. Each polypeptide 
is defined by its CE-migration time (x-axis, minutes), mass (y-axis, kDa), and signal intensity 
(z-axis). The molecular mass is indicated on the left, the normalized migration time is indicated 
on the bottom.
Results
The case/control study was composed of 148 diabetes mellitus type 2 patients, 
including 65 cases and 83 controls. The patients were well-matched for age, gender 
and diabetes duration. Blood pressure was significantly higher, and creatinine 
clearance significantly lower in cases (all p<0.05). Albuminuria was by definition 
present in cases, and absent in control. All samples were analyzed with CE-MS. For 
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MS data sets were obtained. The data obtained from 3 samples did not pass quality 
control and were excluded from the subsequent analysis. Patient characteristics and 
classification scores of the proteome analysis are presented in table 1. 













cases 64 44/20 64±10 17±8 143±21 78±12 953±931 72±40
controls 81 47/34 62±11 16±6 133±15 74±11 6±4 94±32
 
M/F: male/female ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; UAE: 
urinary albumin excretion; CrCl: creatinine clearance estimated by Cockroft-Gault equation.
Rossing et al. defined and validated models for the differentiation of diabetic 
patients type 1 with macroalbuminuria and normoalbuminuria after CE-MS analysis 
[1]. A support vector machine biomarker model (SVM-BM) composed of 65 of 
these biomarkers identified DN in blinded data set with 100% sensitivity and 97% 
specificity. This ‘DN model’, was applied to the collected ‘case and control’ samples 
of the PREDICTIONS study cohort. After evaluation of the blinded samples, all data 
were reported to the central study database for further evaluation and subsequent 
unblinding. After unblinding, accuracy of prediction was assessed. The complete 
polypeptide profiles and the DN-specific panels are depicted in figure 1 exemplarily 
for one patient with and one without DN. 
Classification of the ‘case/control’ urine samples with this ‘DN biomarker model’ was 
accomplished with sensitivity of 93.8% and specificity of 91.4%. The AUC value in 
the ROC-analysis was 0.948 [95% CI: 0.898 to 0.978] (see figure 2A). As depicted 
in the Box-and-Whisker plot in figure 2B, this classification resulted in a significant 
(P<0.0001) difference of the median classification factor between patients with 
DN (0.889 [95% CI: 0.843 to 0.924]) and patients without DN (-0.461 [95%°CI: 
-0.592 to -0.255]). The classification results are shown in table S2 (‘DN model’). 
Of the 65 previously defined differentially expressed peptides [1], in the current 
study 92.3% (60 markers) could be confirmed as being significantly different in this 
PREDICTIONS cohort between diabetic patients with DN and diabetic controls at 














































































































































Figure 2: Statistical analysis of the classification results.
(A) ROC curve and (B) Box-Whisker-plot for classification of the ‘case and control’ patient 
collective with the ‘DN’ pattern are shown.
A correlation analysis of these classification factors and the clinical parameters 
was performed (see figure 3). In figure 3A the correlation with log urinary albumin 
excretion (UAE) is demonstrated with a positive correlation coefficient r=0.701 [95% 
CI: 0.607 to 0.775] and a significance level of P<0.0001. Here, most of the urine 
samples from patients without DN (<20mg/L) have classification factors below 0.3 
and from patients with DN (<200mg/L) have classification factors above 0.5. The 
correlation analysis of the proteomic results with the creatinine clearance (CrCl) 
(see figure 3B) resulted in a negative correlation (r=-0.368 [95% CI: -0.501 to -0.218] 
(P<0.0001)), which is lower than the correlation with urinary albumin excretion. Many 
patients with a classification factor above 0.5 also show a CrCl <90 ml/min/1.73m2. 















































































































































          
  
Figure 3: Correlation analysis. 
Scatter diagrams of correlation from proteomic biomarker pattern with urinary albumin 
excretion (UAE) (A) and creatinine clearance (B). The red line shows the regression line with 
95% confidence interval (dashed line).
34 of the 65 biomarkers could be sequenced until today. We have identified 8 more 
peptides in comparison to in the previous study [1], where the used biomarker 
pattern was generated. For the sequenced peptides the direction of regulation 
is illustrated in figure 4 and 5. Up-regulated markers in urine samples of patients 
with DN (see figure 4) are fragments of blood components, like alpha-1-antitrypsin, 
albumin, transthyretin, alpha-2-HS-glycoprotein, and beta-2-microglobulin. In figure 
5 the regulation of CD99 antigen fragment, collagen fragments, membrane associated 
progesterone receptor component 1 fragment, and uromodulin fragment is shown. 
Only one collagen fragment is up-regulated in urine samples of DN patients. This 
peptide belongs to the five biomarkers, which are not significant different between 















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: Up-regulation of blood derived protein fragments in urine samples of the 
PREDICTIONS cohort. 
Displayed is the regulation of alpha-1-antitrypsin fragments, an alpha-2-HS glycoprotein 
fragment, a beta-2-microglobulin fragment, serum albumin fragments, and a transthyretin 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5: (Down-) Regulation of further peptide markers in urine samples of the PREDICTIONS 
cohort.
Displayed is the regulation of a CD99 antigen fragment, different collagen fragments, membrane 
associated progesterone receptor component 1 fragment, and uromodulin fragment. The hash 
(#) depicts peptide fragments, which are not significant in this cohort. The asterisk (*) indicate 
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In addition, a Rank correlation of each of the 65 biomarker was performed. All 
biomarkers, which presented a significant correlation, have reciprocal correlation 
coefficients for UAE and CrCl. As expected the correlation between albumin excretion 
and known albumin and other blood protein fragments is positive, in contrast to 
the correlation of albumin excretion with the collagen fragments, CD99 antigen, 
membrane-associated progesterone receptor component 1, and uromodulin 
fragments. Furthermore, the correlation of UAE with blood protein fragments is 
stronger than the correlation with collagen fragments. The five biomarkers, which are 
not significant in the U-test, also show no significant correlation to urinary albumin 
excretion. The Rank correlation of creatinine clearance with collagen fragments and 
blood protein fragments is not very high in both cases. 
Investigation of the false positive classified patients indicated that in several cases 
the classification “diabetic renal damage” may in fact be correct, but albuminuria 
may be under the respective criteria (see method section: ‘Methods’). Seven ‘control’ 
patients were classified as cases. All of them show GFR values below 90 (stage 2), 
three of them even have a GFR<60 (stage 3), and two of them have an increasing 
urinary albumin excretion at a later visit (approximately 1 year later). These data may 
indicate the utility of the biomarkers not only for detection of overt nephropathy, but 
also prediction of its development in patients with diabetes and normoalbuminuria.
For the generation of a new model for DN in diabetic type 2 patients (using the 
PREDICTIONS cohort), urinary polypeptides of the control group were compared with 
those of patients with diabetic nephropathy. This analysis identified 103 peptides of 
statistical significance using multivariate statistic analysis like Benjamini-Hochberg 
[40] (p=0.05). A support vector machine-based model with these biomarkers 
discriminated controls from cases with 98% sensitivity and 99% specificity. The 
distribution of the polypeptides in the two groups is shown in figure 6A. The validity of 
the ‘DN type 2’ biomarkers was further evaluated in a diabetes type 1 test-set cohort 
(trainingset of Rossing et al. [1]) and resulted in 86% sensitivity and 100% specificity 
with an AUC value of 0.948 (see figure 6B). Of the 103 defined differentially expressed 
peptides, 65% (67 markers) could be confirmed as also being significantly different 
in the ‘Rossing’ cohort between diabetic patients with DN and diabetes controls. Of 








































































































































           
 
Figure 6: ROC curves for classification of the patient collectives with the ‘DN type 2’ pattern. 
ROC analysis for CKD diagnosis of the training set (A) and the test set (B).
dIsCussIon
This study provides independent confirmation of the performance of a previously 
developed biomarker model for diabetic nephropathy using proteomic analysis with 
high-resolution CE-MS of the urinary proteome [1, 41]. The model for DN has high 
specificity and sensitivity, notwithstanding the fact that the current study was done 
in subjects with type 2 diabetes, whereas the population used for development of 
the model for diagnosis of diabetic nephropathy had diabetic mellitus type 1. These 
findings clearly indicate that the applied peptide pattern allowed diabetes-type 
independent classification of diabetic nephropathy. 
For most of the peptides in the ‘DN model’, the difference between the cases and 
controls reached a high level of statistical significance, with p-values <0.0001, 
demonstrating the high selectivity of the urinary proteome analysis. The fact that 92% 
of the markers included in the ‘DN model’ were also significant in the PREDICTIONS 
cohort supports a valid strategy of marker selection in the Rossing study [1].
When distinguishing patients with DN from normoalbuminuric diabetic patients, the 
distribution of the classification factors in the control group (patients without DN) 
was broader than in the case group (see figures 2B and 3A). This may be explained by 
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arrangement of the case and control group was performed based on classical urine 
analyses (urinary albumin excretion rate). 
Identification of the specific peptides in the biomarker model may allow better 
insights in patho-physiological pathways involved in renal damage in general, and 
specific pathways for renal damage in diabetes. The regulation of the sequenced 
biomarkers in the ‘DN model’, as reported here, shows a consistent pattern that is 
apparently specific for DN. The up-regulation of the serum protein fragments and 
the down-regulation of the collagen fragments in the urine is a consistent feature of 
DN, as also discussed in detail in the literature (see [6]). Furthermore, the correlation 
analysis confirms these findings. As expected, the correlation of the biomarkers with 
UAE and with CrCl resulted in reciprocal values.
Thousand-fold up-regulation of blood-derived protein fragments in urine (see 
figure 3B) is expected in the light of substantial glomerular damage that results 
in albuminuria. Hence, this likely does not reflect better or earlier markers. The 
presence of high amounts of these proteins likely indicates an insufficiency of 
readsorption or altered glomerular permeability of the kidney, implying an existing 
damage. In contrast, changes in the collagen metabolism may be closely linked to 
early renal damage in patients with diabetes and may help to provide information 
for the prognosis and monitoring of DN [1]. Type I and III collagens alpha-1 are 
main components of renal interstitial fibrosis [42]. It is tempting to speculate that 
the decrease in urinary collagen fragments reflects decreased collagen breakdown, 
and hence a propensity to progressive fibrotic lesions. However, the origin of the 
urinary collagen fragments cannot be determined from the current data and must 
be investigated in further studies. The differential excretion of uromodulin fragments 
gains additional interest from the recently reported association between genetic 
variation in the coding for uromodulin with susceptibility to CKD [43]. Finally, altered 
collagen metabolism appears to be involved in non-diabetic CKD as well, albeit with a 
differential excretory pattern. The patho-physiological impact of this finding deserves 
further exploration. 
Investigation of the few cases where the classification factors of the DN model did 
not coincide with the clinical diagnosis suggests that several of these may in fact not 





































was not correct (see also figure 3A: classification factor >0.3 and UAE <10mg/L). 
Of the 7 controls that were classified as cases, all patients had at least GFR below 
90, indicating the presence or the possible onset of renal disease. It is tempting 
to speculate that these patients may well have developed a diabetic renal disease 
that does not exactly resemble “classical DN”, hence is undetected by assessing 
albuminuria only.
The generation of a new model for DN with type 2 diabetic patients (PREDICTINS 
cohort) and the validation of this model with type 1 diabetic patients (Rossing 
cohort), resulted in the same AUC value as the validation of the previously defined 
‘DN type 1’ model with the PREDICTIONS cohort. The differences in the biomarker 
selection/identification in type 1 and 2 diabetic patient urine samples may be caused 
by different patho-physiology of the DN, but also by the differences in both cohorts 
in general. The groups differ in age (~10 years), diabetes duration (~20 years), 
and medication (e.g. insulin). Therefore, this study is not suited for the analysis of 
differences of DN derived from type 1 or 2 diabetes. Also, the investigation of such 
potential differences was not a focus of this study. This will require greater population 
sizes and external validation of training profiles and components of profiles in 
independent populations of subjects with type 1 and type 2 diabetes and should be 
the focus of a further study.
In conclusion, urinary profiling using CE-MS was successfully applied to urine 
samples of an independent population of diabetic patients with or without existing 
DN. A biomarker model for the identification of patients with DN was validated with 
this multicenter blinded test set and allowed diagnosis of DN with high accuracy. 
These results provide clear independent confirmation for the accuracy of urinary 
proteome analysis for detection of DN. As these biomarkers have now been validated 
in independent clinical centers, we will in the next step investigate their prognostic 
value. Albumin excretion does reflect late pathological changes. However, we are 
tempted by the data presented to speculate that the assessment of urinary collagen 
fragments may result in a substantial improvement, enabling detection of diabetic 
nephropathy at earlier stages. This is also indicated by preliminary data on small 
populations ([1] and unpublished). As a next step, these promising data have to be 
verified in longitudinal studies of sufficient statistical power to prove, or disprove, 
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Chapter 6
A double-blind randomized placebo-controlled 
clinical trial on benfotiamine treatment in patients 
with diabetic nephropathy
Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, 
Mijnhout GS, Bilo HJG, Gans ROB, Navis GJ, Bakker SJL







































Benfotiamine, a lipid-soluble thiamine derivative, have been suggested as an agent 
that can prevent occurrence and deterioration of diabetic complications, including 
diabetic nephropathy. We aimed to investigate the effect of benfotiamine on urinary 
excretion of albumin (UAE) and the tubular damage marker kidney injury molecule 1 
(KIM-1) in patients with type 2 diabetes and nephropathy.
Methods
In this double-blind, placebo-controlled trial, patients with type 2 diabetes and 
high-normal to micro-albuminuria (UAE 15-300 mg/24h) despite use of angiotensin-
converting enzyme inhibitors (ACE-I) or angiotensin-receptor blockers (ARB), were 
randomly assigned to receive 12-week treatment with benfotiamine (900mg/day) 
or placebo. Thiamine status was assessed by whole blood thiamine concentrations, 
erythrocyte transketolase activity, and thiamine pyrophosphate effect. Primary 
outcome measures were 24h-UAE and 24h urinary KIM-1 excretion.
Results
In 39 patients assigned to benfotiamine and 43 patients assigned to placebo, median 
[interquartile range] baseline 24h-UAE was 90 [38; 267] vs 97 [48; 177] mg/24h, 
respectively, and 24h-KIM-1 was 1.67 [0.9; 2.4] vs 1.56 [1.1; 1.9] μg/24h respectively. 
Benfotiamine treatment resulted in significant improvement in all three domains of 
thiamine status (P <0.001). After 12 weeks of treatment with benfotiamine, there 
were no significant reductions in 24h-UAE and 24h-KIM-1 compared to placebo 
(∆UAE: -9 [-53; 34] vs -7 [-56; 65] mg/24h respectively, P=0.36; ∆KIM-1: -0.014 [-0.23; 
0.56] vs -0.043 [-0.36; 0.19] μg/24h respectively, P=0.09).
Conclusions
In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment 
for 12 weeks as add-on therapy to ACE-I or ARB did not reduce urinary excretion of 







































The incidence of diabetes related complications, like diabetic nephropathy (DN), 
increases, also in the perspective of the worldwide increase in prevalence of type 
2 diabetes mellitus [1]. Diabetes has become the leading cause of end-stage renal 
disease (ESRD), with in some countries more than 40% of all new cases of ESRD 
occurring in patients with diabetes [2].
ESRD caused by diabetes can be explained by different pathophysiological 
mechanisms, including induction of glomerular endothelial damage, which in turn 
leads to albuminuria [3]. Albuminuria as such also plays an etiological role inducing 
tubulointerstitial inflammation and fibrosis with increasing albuminuria [4, 5].
Improving glycaemic control has shown to reduce the risk of the development of 
microalbuminuria [6, 7]. Once established, reduction of albuminuria, in particular 
by using angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin-receptor 
blockers (ARBs), is the cornerstone in preventing or retarding the occurrence of ESRD 
[8, 9]. Despite this successful therapy, there are still people with diabetes progressing 
to ESRD. Therefore, there is a great need for further adjunctive treatments which can 
help to prevent ESRD.
Recently, patients with type 1 and type 2 diabetes were found to have low plasma 
thiamine concentrations, due to increased thiamine loss with urine [10]. Additionally, 
thiamine and benfotiamine have recently been proposed as agents that can prevent 
occurrence and deterioration of diabetic complications [11, 12]. Benfotiamine is a 
lipophilic thiamine derivative with higher bioavailability compared to thiamine [13]. 
In animal experimental studies, benfotiamine has a beneficial effect on microvascular 
complications [12, 14].
We aimed to investigate whether additional treatment with benfotiamine in patients 
with type 2 diabetes and increased urinary albumin excretion rate on ACE-Is or ARBs 








































Participants were recruited from the outpatient department population of the 
Isala Clinics in Zwolle, The Netherlands. Inclusion criteria were diagnosis of type 2 
diabetes according to American Diabetes Association criteria [15], age between 40 
and 75 years, active DN as indicated by urinary albumin excretion (UAE) in the high-
normal or microalbuminuric range (UAE 15-300 mg/24-hour urine, or spot urine 
albumin/creatinine 1.25-25 mg/mmol in males and 1.75-35 mg/mmol in females) 
in at least two out of three samples within 2-6 weeks in advance of inclusion in the 
trial despite treatment with ACE-Is and/or ARBs in an unchanged dose for at least 
3 months, glycated hemoglobin (HbA1c) < 8.5% and estimated glomerular filtration 
rate calculated using the Modification of Diet in Renal Disease formula [16] (eGFR-
MDRD) > 30 ml/min. Exclusion criteria were participation in another study ≤ one 
month before joining this study, renal impairment by causes other than diabetes, 
liver enzymes (AST and ALT) ≥ three times upper limit of normal values (normal 
values: AST < 40 IU/L, ALT < 45 IU/L), hyper-/hypothyroidism, a blood pressure > 
160/90 mmHg, severe cardiac function disturbances or heart rhythm disturbances, 
neoplasm, severe general diseases or mental disorders, drug abuse, pregnancy or 
lactation, active menses during the past year, hypersensitivity to benfotiamine or 
other constituents of the study medication, use of vitamin B-containing supplements 
during the last 3 months and use of nonsteroidal anti-inflammatory drugs more than 
3 times per week. Additionally, it was required that no changes had been made in 
prescription of cholesterol lowering medication, blood pressure lowering drugs and 
oral hypoglycaemic agents during 3 months prior the study. In total 2711 patients 
registered in our local Diabetes Electronic Management System (DEMS) were 
screened for eligibility [17]. Those who fulfilled inclusion criteria were informed 
about the study by sending information per mail. Patients who accepted were 
included after written informed consent was obtained. This trial was conducted in 
accordance with the Helsinki Declaration, approved by the medical ethics committee 








































Patients were randomised to benfotiamine 300 mg t.i.d. (daily dose 900mg) or placebo 
for 12 weeks. Benfotiamine and placebo tablets were prepared by Wörwag pharma 
(Böblingen, Germany) and packed in numbered boxes, unrecognized from each 
other, according to a computer-generated randomisation list which was prepared by 
an independent statistician. Independent pharmacists dispensed the medication box 
with the lowest available number to each patient. Neither the researchers nor the 
patients knew into which group they had been allocated.
During a run-in phase, patients were instructed how to collect 24-hour urine and 
asked not to change their usual diet or daily activity during the study, particularly 
during the week preceding their clinical visits. Patients were instructed to take one 
tablet after the three main meals, every day. In case of suspected side effects, patients 
were asked to contact the study physician who instructed them to stop the study 
medication until disappearance of complaints for a maximum of one week. When 
complaints disappeared, study medication was resumed once again. All participants 
were evaluated at baseline, after 6 weeks, and after 12 weeks of treatment. Patients 
were asked to deliver a 24-hour urine collection to the laboratory on each visit. At 
the laboratory, additional morning spot-urine sample and blood samples were taken. 
On the last visit, tablets were counted to assess compliance. Non-compliance was 
considered if less than 80% of the study medication had been taken. At the end of 
the study, after data collection and laboratory analyses had been completed, the 
randomisation list was provided to the researchers for unblinding.
Laboratory analyses
Thiamine concentration was measured in whole blood by HPLC, reference range 90-
200 nmol/l, lower limit of detection 10 nmol/L, upper limit of detection 300 nmol/l 
[18]. Erythrocyte transketolase (TK)-activity (expressed in mU/mgHb) and thiamine 
pyrophosphate (TPP) effect (expressed as %) were measured according to the 
kinetic method of Chamberlain et al [19] in washed erythrocyte samples after being 
haemolysed by mixing with Aqua Purificata. Reagents were purchased from Sigma 
Aldrich® (Gillingham, United Kingdom). Thiamine deficiency was considered present 





































completed the study. Urinary albumin was measured by immunonephelometry 
(Behring Nephelometer, Mannheim, Germany) with a threshold of 1.8-2.3 mg/l and 
intra- and inter-assay coefficients of variation of less than 2.2 and 2.6%, respectively. 
Urinary kidney injury molecule-1 (KIM-1) was measured by ELISA, lowest limit of 
detection: 0.12 ng/ml, intra- and inter-assay coefficients of variation: 7.9% and 
14.4%, respectively [21]. The other tubular markers, neutrophil gelatinase-associated 
lipocalin (Ngal, R&D Systems, Abingdon, UK) and α1-microglobulin (α1-m, Fitzgerald, 
Concord MA, USA; ICL Inc, Newberg, OR,  USA), were measured using routine ELISA 
and competitive EIA assays, respectively. Cystatin C was measured by immunoassay 
(Gentian-AS, Moss, Norway). HbA1c was measured with Primus Ultra2 system using 
high-performance liquid chromatography. Other laboratory measurements were 
performed according to standard hospital procedures. Creatinine clearance was 
calculated from 24-hour urinary creatinine excretion and plasma creatinine.
Statistical analyses
Normally distributed variables are presented as means ± standard deviations (SD) 
and variables with a skewed distribution as medians and interquartile ranges (IQR). 
Q-Q plot was used to assess whether variables were distributed normally or skewed. 
χ2 test was used to compare non-continuous variables. Changes were analyzed by 
ANOVA for repeated measurements. P-values for change over time are presented. 
Additionally, changes in outcome measures from baseline to 6 weeks (∆ 6 weeks) and 
from baseline to 12 weeks (∆ 12 weeks) were computed. Positive changes indicate 
increase over time and negative changes indicate decrease over time. Comparisons 
of changes in primary and secondary parameters between groups were performed 
by an unpaired Student’s t-test (in case of normal distribution) or Mann-Whitney-U 
test (in case of skewed distribution). Multivariate regression analysis was used to 
adjust for baseline differences between groups.
To test our hypothesis that benfotiamine reduces 24-hour urinary excretion of 
albumin and KIM-1 (primary outcome measures), 38 evaluable patients per group 
were required to detect an effect of size 0.65 (power 80%, α = 0.05, one-sided test). 
To compensate for possible drop-out, we planned to enroll 43 patients per group. 
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urine and spot morning urine samples, 24-hour urinary excretion of tubulointerstitial 
damage markers (α1-m and Ngal), and ratios of these markers and KIM-1 over 
creatinine concentration in 24h urine collections. A P-value of 0.05 or less was 
considered statistically significant. One-sided P-values were calculated for primary 
outcome measures and two-sided P-values were calculated for the other outcome 
measures. Statistical analyses were done by using a commercially available program 
(SPSS for Windows, version 16.0., Chicago, IL, USA).
Intention-to-treat analysis and per-protocol analysis were planned. In case of drop-
out, data was not replaced and these patients had then to be excluded from analysis. 
Non-compliance and change in concomitant medications (including ACE-I or ARB) 
were considered as deviations from study protocol that lead to exclusion from per-
protocol analysis.
Results
Patient flow and baseline characteristics at randomization
Participants were recruited from February 2008 till February 2009. A CONSORT 
diagram of the study is shown in figure 1.
43 patients were randomized to benfotiamine and 43 to placebo. In the benfotiamine 
group, 2 patients did not complete the study because of newly diagnosed malignancy 
(lung cancer and stomach cancer, both were considered not causally related to study 
medication) and 2 others withdrew informed consent (one complained of dizziness 
and the other complained of urticaria and dry mouth). Because of this missing follow-
up data, 39 patients out of 43 were analyzed in this group. In the placebo group, all 
patients finished the study and were analyzed. Baseline characteristics of the two 














































212 Invited for further 
screening 
126 Excluded 
41 Did not meet 
inclusion 
criteria 
85 Refused to 
participate 
86 Randomised 
43 Allocated to benfotiamine and 
received benfotiamine 
 
43 Allocated to placebo and  
received placebo 
 
4 Drop out and lost 
to follow up 
2 Adverse effects 
2 Illness 
0 Drop out and lost 
to follow up 
 
 
43 included in analysis 39 Included in analysis 
40 included per-protocol 
analysis 
39 Included in per-protocol 
analysis 




2 Change in co-
medication 






2711 Participants assessed for 
eligibility 
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      n 39 43
        Age (years) 65.3 ± 5.9 64.6 ± 6.1 0.63
        Males 30 (76.9) 33 (76.7) 0.98
        BMI (kg/m2) 32.1 ± 5.1 31.9 ± 5.9 0.93
        Duration of diabetes (years) 12 [9; 18] 10 [7; 18] 0.41
        Systolic blood pressure (mmHg) 140 ± 16 137 ± 20 0.48
        Diastolic blood pressure (mmHg) 76 ± 8 76 ± 10 0.91
        Smoking 10 (26) 10 (24) 0.72
        Insulin treatment 31 (79) 29 (67) 0.22
        Oral hypoglycemic agents 19 (49) 29 (67) 0.05
        HbA1c (%) 7.3 ± 0.9 7.4 ± 0.9 0.55
        LDL-cholesterol (mmol/L) 1.9 ± 0.7 1.8 ± 0.9 0.37
        HDL-cholesterol (mmol/L) 1.2 ± 0.3 1.1 ± 0.3 0.18
        Triglycerides (mmol/L) 1.8 [1.4; 2.6] 2.1 [1.4; 3.4] 0.11
        Serum creatinine (µmol/L) 84 ± 19 87 ± 23 0.51
        Creatinine clearance (mL/min) 135 ± 51 130 ± 58 0.69
Cystatin C (mg/l) 1.01 ± 0.21 1.03 ± 0.23 0.66
Thiamine status
        Thiamine (nmol/L) 126  ± 23 120 ± 23 0.39
        Transketolase activity (mU/mgHb) 0.41 ± 0.10 0.38 ± 0.11 0.69
        TPP effect (%) 6.2 [1.0; 11.6] 9.1 [4.6; 15.5] 0.15
        TPP effect > 15% 6 (15) 10 (23) 0.37
Primary outcome parameters
        UAE (mg/24 hours) 90 [38; 267] 97 [48; 177] 0.70
        KIM-1 (µg/24 hours) 1.67 [0.9; 2.4] 1.56 [1.1; 1.9] 0.73
Secondary outcome parameters
        Spot urine UACR (mg/mmol) 10.3 [3.7; 23.4] 7.6 [4.3; 13.3] 0.60
        24h UACR (mg/mmol) 9.3 [2.4; 16.8] 6.2 [3.4; 10.5] 0.47
        KIM-1/creatinine (ng/mmol) 103 [63; 158] 99 [79; 141] 0.96
        Urinary α1-m (mg/24 hours) 9.4 [4.3; 24.4] 8.2 [4.3; 20.3] 0.96
        Urinary α1-m/creatinine (mg/mmol) 0.57 [0.28; 1.38] 0.64 [0.30; 1.35] 0.78
        Urinary Ngal (mg/24 hours) 131.5 [66.8; 226.8] 122.2 [53.5; 224.2] 0.73
        Urinary Ngal/creatinine (mg/mmol) 6.68 [4.25; 13.91] 7.68 [4.22; 18.86] 0.93
Data are n (%), mean ± standard deviation, or median [interquartile range]. HbA1c,, glycated 
hemoglobin; TPP, thiamine pyrophosphate; UAE, urinary albumin excretion; KIM-1, kidney 
injury molecule-1; UACR, urinary albumin-creatinine ratio; α1-m, α1-microglobuline; Ngal, 






































Effects of intervention on thiamine status are shown in figure 2. In patients receiving 
benfotiamine, whole blood thiamine concentrations increased, reaching the upper 
limit of detection (300 nmol/l) in all patients at 12 weeks. Erythrocyte TK-activity 
also significantly increased after 12 weeks of treatment in the benfotiamine group 
compared to placebo (median [IQR] change after 12 week 0.13 [0.05; 0.18] versus 
0.04 [-0.03; 0.06] mU/mgHb in benfotiamine and placebo, respectively, P<0.001). 
Concomitantly, there was a significant decrease in TPP-effect in the benfotiamine 
group (median [IQR] change after 12 week -9.9 [-14.1; -3.6] % versus -1.4 [-9.9; 3.6] 
% in benfotiamine and placebo, respectively, P= 0.002). At 12 weeks, no patients 
in the benfotiamine group and 2 patients (5%) in the placebo group had thiamine 





TK, transketolase; TPP, thiamine pyrophosphate. *<0.05 **<0.01; ***<0.001, compared with 
























































































































TK, transketolase; TPP, thiamine pyrophosphate. *<0.05 **<0.01; ***<0.001, compared with 
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Figure 2: Effects of intervention on thiamine status parameters after 6 and 12 weeks according 
to group (benfotiamine vs placebo)
A. mean values and standard deviations of blood thiamine concentration,
B. mean values and standard deviations of eryt rocyte transketolase activity,
C. median values and interqu rtile ranges of TPP effect.
 
TK, transketolase; TPP, thiamine pyrophosphate. *P<0.05 **P<0.01; ***P<0.001, compared 





































Table 2: Summary of absolute changes in primary outcome, secondary outcome, and clinical 




∆ 6 weeks -3 [-57; 51] 12 [-61; 40] 0.37
∆ 12 weeks -9 [-53; 34] -7 [-56; 65] 0.36
Urinary KIM-1 excretion (µg/24h)
∆ 6 weeks 0.084 [-0.16; 0.36] -0.100 [-0.35; 0.17] 0.02
∆ 12 weeks -0.014 [-0.23; 0.56] -0.043 [-0.36; 0.19] 0.09
Secondary outcome parameters
24h UACR (mg/mmol)
∆ 6 weeks -0.2 [-7.0; 3.4] -0.1 [-2.6; 1.6] 0.74
∆ 12 weeks -0.1 [-4.3; 2.1] -0.1 [-3.3; 4.6] 0.40
Spot urine UACR (mg/mmol)
∆ 6 weeks -0.7 [-4.9; 1.7] -1.4 [-4.6; 2.2] 0.94
∆ 12 weeks -0.4 [-8.2; 2.4] 1.1 [-3.4; 3.5] 0.21
Urinary KIM-1/creatinine (ng/mmol)
∆ 6 weeks -4 [-22; 40] 11 [-41; 9] 0.14
∆ 12 weeks 2 [-26; 27] 4 [-37; 14] 0.55
Urinary α1-m excretion (mg/24h)
∆ 6 weeks 0.4 [-3.9; 7.1] 0.8 [-7.5; 5.9] 0.94
∆ 12 weeks 0.4 [-5.2; 5.3] -0.2 [-7.8; 5.6] 0.63
Urinary α1-m/creatinine (mg/mmol)
∆ 6 weeks 0.05 [-0.42; 0.52] -0.01 [-0.65; 0.37] 0.60
∆ 12 weeks 0.05 [-0.17; 0.32] -0.02 [-0.70; 0.39] 0.54
Urinary Ngal excretion (mg/24h)
∆ 6 weeks -0.8 [-19; 23] -0.9 [-18; 17] 0.97
∆ 12 weeks 3.8 [-17; 31] -4.2 [-19; 2] 0.08
Urinary Ngal/creatinine (mg/mmol)
∆ 6 weeks 0.54 [-3.45; 3.61] -0.73 [-4.24; 1.22] 0.33
∆ 12 weeks -1.23 [-3.64; 1.40] 0.37 [-3.08; 2.39] 0.23
Clinical characteristics
Systolic blood pressure (mmHg)
∆ 6 weeks -1 [-9; 9] 6 [-9; 16] 0.25
∆ 12 weeks 0 [-6; 11] 4 [-7; 14] 0.98
Diastolic blood pressure (mmHg)
∆ 6 weeks 1 [-5; 6] -1 [-6; 5] 0.59
∆ 12 weeks 1 [-5; 6] 0 [-5; 6] 0.95
HbA1c (%)
∆ 6 weeks -0.1 [-0.4; 0.1] -0.1 [-0.4; 0.1] 0.78







































∆ 6 weeks 6 [0; 9] 2 [-4; 5] 0.08
∆ 12 weeks 4 [0; 8] 0 [-3; 4] <0.001
Creatinine Clearance (ml/min)
∆ 6 weeks 0 [-21; 21] 5 [-24 ; 40] 0.35
∆ 12 weeks 3 [-29; 34] 4 [-34; 24] 0.92
Cystatine C
∆ 6 weeks -0.05 [-0.30; 0.14] 0.13 [-0.20; 0.36] 0.10
∆ 12 weeks 0.04 [-0.22; 0.34] 0.05 [-0.28; 0.46] 0.72
LDL-cholesterol (mmol/l)
∆ 6 weeks -0.05 [-0.30; 0.14] 0.13 [-0.20; 0.36] 0.10
∆ 12 weeks 0.04 [-0.22; 0.34] 0.05 [-0.28; 0.46] 0.72
HDL-cholesterol (mmol/l)
∆ 6 weeks -0.06 [-0.12; 0.06] 0.02 [-0.05; 0.10] 0.02
∆ 12 weeks -0.01 [-0.07; 0.13] 0.02 [-0.07; 0.10] 0.66
Triglycerides (mmol/l)
∆ 6 weeks 0.17 [-0.16; 0.67] -0.13 [-0.66; 0.20] 0.01
∆ 12 weeks -0.13 [-0.52; 0.60] -0.28 [-0.55; 0.11] 0.18
Data are median [interquartile range]; ∆ 6 weeks/12 weeks, change from baseline to 6 
weeks/12weeks; UAE, urinary albumin excretion; KIM-1, kidney injury molecule-1; UACR, 
urinary albumin-creatinine ratio; α1-m, α1-microglobuline; Ngal, neutrophil gelatinase 
associated lipocalin; HbA1c, glycated hemoglobin; eGFR-MDRD, estimated glomerular filtration 





































Table 3: Baseline characteristics and changes in thiamine status parameters, primary outcome 
measures, secondary outcome measures, and clinical characteristics over time
Benfotiamine (n = 39)
Baseline 6 weeks 12 weeks
Baseline characteristics
Males (n (%)) 30
Age (years) 65.3 ± 5.9
BMI (kg/m2) 32.1 ± 5.1
Duration of diabetes (years) 12 [9; 18]
Insulin treatment (n (%)) 31 (79)
Oral hypoglycaemic agents (n (%)) 19 (49)
Plasma thiamine (nmol/l) 31.8 ± 7.7
Thiamine status
Thiamine (nmol/L) 126 ± 23 290 ± 31 300 ± 0
TK-activity (mU/mgHb) 0.41 ± 0.10 0.51 ± 0.12 0.53 ± 0.15
Primary outcome parameters
UAE (mg/24h) 90 [38; 267] 75 [49; 280] 72 [38; 199]
U-KIM-1 (µg/24h) 1.67 [0.95; 2.47] 1.51 [0.86; 2.59] 1.68 [1.06; 2.40]
Secondary outcome parameters
24h UACR (mg/mmol) 10.3 [3.7; 23.4] 6.1 [3.0; 17.7] 4.9 [2.5; 18.4]
Spot urine UACR (mg/mmol) 9.3 [2.4; 16.8] 5.8 [3.7; 17.9] 7.1 [3.6; 17.8]
U-KIM-1/creatinine (ng/mmol) 103 [63; 158] 95 [66; 170] 96 [77; 148]
U-α1m (mg/24h) 9.4 [4.3; 24.4] 11.9 [4.4; 20.2] 11.2 [4.1; 18.8]
U-α1m/creatinine (mg/mmol) 0.6 [0.3; 1.4] 0.7 [0.3; 1.3] 0.6 [0.3; 1.2]
U-Ngal (mg/24h) 131 [67; 227] 118 [77; 229] 115 [73; 284]
U-Ngal/creatinine (mg/mmol) 6.7 [4.3; 13.9] 6.2 [3.4; 15.9] 5.1 [3.2; 12.9]
Clinical characteristics
SBP (mmHg) 140 ± 16 139 ± 14 143 ± 17
DBP (mmHg) 76 ± 8 77 ± 10 76 ± 9
HbA
1c (%) 7.3 ± 0.9 7.1 ± 0.9 7.3 ± 1.0
Plasma creatinine (µmol/l) 84 ± 19 89 ± 19 88 ± 20
Creatinine Clearance (ml/min) 135 ± 51 129 ± 53 133 ± 45
Cystatin C (mg/l) 1.01 ± 0.21 1.06 ± 0.22 1.09 ± 0.23
LDL-cholesterol (mmol/l) 1.9 ± 0.7 1.9 ± 0.8 2.1 ± 0.8
HDL-cholesterol (mmol/l) 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3
Triglycerides (mmol/l) 1.8 [1.4; 2.6] 1.9 [1.4; 2.8] 1.7 [1.2; 2.6]
Data are mean ± standard deviation or median [interquartile range]. BMI, body mass index; 
TK, transketolase; UAE, urinary albumin excretion; U-KIM-1, urinray excretion of kidney 
injury molecule-1; UACR, urinary albumin-creatinine ratio; U-α1m, urinary excretion of α1-
microglobulin; U-Ngal, urinary excretion of neutrophil gelatinase-associated lipocalin; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HbA
1c, glycated hemoglobin. Comparison 
of baseline characteristics was performed by unpaired Student’s t-test (for normally distributed 
variables) or Mann-Whitney-U test (for non-normally distributed variables). x2-test was used 
to compare non-continuous variables. Changes in thiamine status parameters, primary 
outcome measures, secondary outcome measures, and clinical characteristics over time were 
analyzed by ANOVA for repeated measures, with log-transformation of variables with skewed 
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Table 3: Baseline characteristics and changes in thiamine status parameters, primary outcome 
measures, secondary outcome measures, and clinical characteristics over time
Benfotiamine (n = 39)
Baseline 6 weeks 12 weeks
Baseline characteristics
Males (n (%)) 30
Age (years) 65.3 ± 5.9
BMI (kg/m2) 32.1 ± 5.1
Duration of diabetes (years) 12 [9; 18]
Insulin treatment (n (%)) 31 (79)
Oral hypoglycaemic agents (n (%)) 19 (49)
Plasma thiamine (nmol/l) 31.8 ± 7.7
Thiamine status
Thiamine (nmol/L) 126 ± 23 290 ± 31 300 ± 0
TK-activity (mU/mgHb) 0.41 ± 0.10 0.51 ± 0.12 0.53 ± 0.15
Primary outcome parameters
UAE (mg/24h) 90 [38; 267] 75 [49; 280] 72 [38; 199]
U-KIM-1 (µg/24h) 1.67 [0.95; 2.47] 1.51 [0.86; 2.59] 1.68 [1.06; 2.40]
Secondary outcome parameters
24h UACR (mg/mmol) 10.3 [3.7; 23.4] 6.1 [3.0; 17.7] 4.9 [2.5; 18.4]
Spot urine UACR (mg/mmol) 9.3 [2.4; 16.8] 5.8 [3.7; 17.9] 7.1 [3.6; 17.8]
U-KIM-1/creatinine (ng/mmol) 103 [63; 158] 95 [66; 170] 96 [77; 148]
U-α1m (mg/24h) 9.4 [4.3; 24.4] 11.9 [4.4; 20.2] 11.2 [4.1; 18.8]
U-α1m/creatinine (mg/mmol) 0.6 [0.3; 1.4] 0.7 [0.3; 1.3] 0.6 [0.3; 1.2]
U-Ngal (mg/24h) 131 [67; 227] 118 [77; 229] 115 [73; 284]
U-Ngal/creatinine (mg/mmol) 6.7 [4.3; 13.9] 6.2 [3.4; 15.9] 5.1 [3.2; 12.9]
Clinical characteristics
SBP (mmHg) 140 ± 16 139 ± 14 143 ± 17
DBP (mmHg) 76 ± 8 77 ± 10 76 ± 9
HbA
1c (%) 7.3 ± 0.9 7.1 ± 0.9 7.3 ± 1.0
Plasma creatinine (µmol/l) 84 ± 19 89 ± 19 88 ± 20
Creatinine Clearance (ml/min) 135 ± 51 129 ± 53 133 ± 45
Cystatin C (mg/l) 1.01 ± 0.21 1.06 ± 0.22 1.09 ± 0.23
LDL-cholesterol (mmol/l) 1.9 ± 0.7 1.9 ± 0.8 2.1 ± 0.8
HDL-cholesterol (mmol/l) 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3
Triglycerides (mmol/l) 1.8 [1.4; 2.6] 1.9 [1.4; 2.8] 1.7 [1.2; 2.6]
Data are mean ± standard deviation or median [interquartile range]. BMI, body mass index; 
TK, transketolase; UAE, urinary albumin excretion; U-KIM-1, urinray excretion of kidney 
injury molecule-1; UACR, urinary albumin-creatinine ratio; U-α1m, urinary excretion of α1-
microglobulin; U-Ngal, urinary excretion of neutrophil gelatinase-associated lipocalin; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HbA
1c, glycated hemoglobin. Comparison 
of baseline characteristics was performed by unpaired Student’s t-test (for normally distributed 
variables) or Mann-Whitney-U test (for non-normally distributed variables). x2-test was used 
to compare non-continuous variables. Changes in thiamine status parameters, primary 
outcome measures, secondary outcome measures, and clinical characteristics over time were 
analyzed by ANOVA for repeated measures, with log-transformation of variables with skewed 
distribution prior to analysis.
Placebo (n = 43) P values
Baseline 6 weeks 12 weeks
33 0.98
64.6 ± 6.1 0.63
31.9 ± 5.9 0.93
10 [7; 18] 0.41
29 (67) 0.22
29 (67) 0.05
31.6 ± 9.8 0.92
122 ± 23 124 ± 25 138 ± 30 <0.001
0.38 ± 0.11 0.39 ± 0.08 0.41 ± 0.10 <0.001
97 [48; 177] 99 [43; 200] 96 [45; 200] 0.36
1.56 [1.06; 1.83] 1.56 [1.06; 1.83] 1.39 [1.02; 2.01] 0.12
7.6 [4.3; 13.3] 7.4 [2.8; 11.0] 7.1 [4.0; 12.5] 0.37
6.2 [3.4; 10.5] 8.2 [3.9; 14.2] 8.1 [4.6; 15.9] 0.58
99 [79; 141] 89 [58; 130] 81 [66; 150] 0.37
8.2 [4.3; 20.3] 9.0 [5.7; 21.1] 10.2 [2.5; 19.7] 0.33
0.6 [0.3; 1.3] 0.6 [0.3; 1.4] 0.7 [0.2; 1.1] 0.47
122 [53; 224] 112 [52; 218] 99 [52; 222] 0.17
7.7 [4.2; 18.9] 6.4 [3.2; 15.1] 8.5 [3.3; 13.1] 0.18
137 ± 20 140 ± 20 140 ± 17 0.60
76 ± 10 76 ± 9 76 ± 10 0.68
7.4 ± 0.9 7.2 ± 0.9 7.2 ± 0.9 0.33
87 ± 23 89 ± 25 87 ± 21 0.04
130 ± 58 139 ± 58 131 ± 64 0.57
1.03 ± 0.23 1.10 ± 0.26 1.11 ± 0.23 0.53
1.8 ± 0.9 1.8 ± 0.9 1.9 ± 0.9 0.55
1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 0.25





































Primary and secondary outcome parameters
Changes in primary outcome parameters, secondary outcome parameters and clinical 
characteristics are shown in table 2 and table 3. Significant differences in primary or 
secondary outcome parameters were neither found after 6 nor after 12 weeks of 
treatment between the benfotiamine group and the placebo group. Change in UAE 
between baseline and 12 weeks was -18mg/24h in the benfotiamine and -1mg/24h 
in the placebo group. For individual differences, respective changes were -9 [-53; 34]
mg/24h and -7 [-56; 65]mg/24h. Adjustment for differences in baseline use of oral 
hypoglycemic agents, and prevalence of TPP>15% in multivariate regression analyses 
did not reveal any relevant different results (data not shown).
With respect to clinical characteristics, there was a trend towards increase in 
plasma creatinine in the benfotiamine group compared to placebo, which reached 
significance after 12 weeks of treatment, but this was not accompanied by changes in 
creatinine clearance or cystatin C In addition, there was a significant increase in serum 
triglycerides (TG) and a significant decrease in HDL-cholesterol in the benfotiamine 
group compared to placebo group at 6 weeks, which were not significant any more 
at 12 weeks.
Side effects
During the study, no serious adverse effects occurred. In the benfotiamine group one 
patient contacted the study physician because of nausea and heartburn. Attempt to 
stop the medication for one week and to retry resulted in symptoms to reappear. 
This patient continued the study with a reduced dose of 1 tablet/day (300mg) and 
was therefore categorised as non-compliant. In the placebo group, one patient was 
non-compliant, as concluded by more than 50 tablets (>20% of the total amount) not 
being taken at the end of the study. Besides, two protocol deviations occurred: ACE-I 
was stopped and antibiotic treatment was initiated for prostatitis in one patient and 
another patient suffered from ACE-I-induced angioedema and was then switched 
to ARB. As a consequence, 38 in the benfotiamine group and 40 in the placebo 
group were available for the per-protocol analysis. The results of these per-protocol 







































In this double-blind placebo-controlled trial, we found that 12 weeks of treatment 
with high-dose benfotiamine did not result in a decrease in urinary excretion of 
albumin or tubulointerstitial damage markers, such as KIM-1, Ngal, and α1-m. On the 
other hand, high-dose benfotiamine did result in improvement in thiamine status, as 
reflected by whole blood thiamine concentrations, erythrocyte TK-activity and TPP 
effect.
Our findings contrast with earlier findings from studies with low dose (7mg/kg) and 
high dose (70 mg/kg) of thiamine and benfotiamine treatment in animal models with 
streptozotocin-induced diabetes, in which 24 weeks of treatment protected against a 
further increase in urinary albumin excretion already after 6 weeks of treatment [12, 
14]. Although no clear evidence of dose-response relationship regarding albuminuria 
was found in these studies, only high-dose benfotiamine suppressed oxidative stress. 
The relatively high dose of benfotiamine (900 mg/day) in our study is still less than 
70mg/kg and might be insufficient to achieve all therapeutic goals in humans.
Our results also contrast with results of a randomised, double-blind placebo-controlled 
pilot study of 12 weeks of high dose (300 mg/day) oral thiamine supplementation in 
40 Pakistani patients with type 2 diabetes [22]. In this study, a median decrease of 
17.7 mg/24h (33%) in UAE within the thiamine treated group was observed after 12 
weeks of treatment.
We investigated the effect of benfotiamine instead of thiamine in addition to existing 
ACE-I or ARB treatment, while in the study by Rabbani et al, more than 50% of the 
patients was not on such treatment [22]. Nevertheless, in a separate analysis of that 
study it was reported that presence or absence of ACE-I/ARB treatment made no 
difference in outcome [23]. Another point is that we investigated Caucasian patients, 
where only about 20% had thiamine deficiency at baseline by the “thiamine effect” 
criterion, while Rabbani et al. investigated Pakistani patients with low plasma 
thiamine concentration. Thus, a difference in basal thiamine status, background diet 
or genetic susceptibility for the effects of benfotiamine/thiamine supplementation 





































In their study in rats, Babaie-Jadidi et al. suggested that benfotiamine has a renal 
hemodynamic effect, antagonizing renal hyperfiltration [12], similar to ACE-I and 
ARB treatment [24]. Consistent with this putative mechanism, we found a small but 
significant increase in plasma creatinine, but this was not paralleled by changes in 
cystatin C or creatinine clearance. Yet, measured glomerular filtration rate would 
have been necessary in order to elucidate renal effects of benfotiamine.
Finding no effect on urinary albumin excretion and tubulointerstitial damage markers 
in patients with type 2 diabetes and DN, it is important to realise that thiamine and 
benfotiamine are supposed to antagonise the detrimental effects of hyperglycaemia. 
In line with this, it has been shown that these agents interfere with at least three 
biochemical pathways by which hyperglycaemia otherwise exerts its detrimental 
effects, including formation of advanced glycation end-products [14]. Still, changes 
may take much time. For example, it took 4-5 years of lowering of HbA1c in patients 
with type 1 diabetes in the Diabetes Control and Complications Trial before a 
difference could be discerned between subjects with strict metabolic control and 
standard therapy regarding urinary albumin excretion rate [6]. Likewise, a similar 
delay in separation of curves was reported in patients with type 2 diabetes in the 
United Kingdom Prospective Diabetes Study [25]. Therefore, given the biology of DN 
and the long duration of detrimental effects of hyperglycaemia to be reversed, it 
is more likely that our study was too short to demonstrate an effect of an agent 
interfering with glucotoxicity. A larger trial with longer follow-up of at least 4 years is 
necessary to investigate possible preventive effects of benfotiamine in DN.
Few adverse events were observed in the benfotiamine group, but none of these was 
serious. Two premature terminations of the study were caused by newly diagnosed 
malignancies; a lung cancer and a stomach cancer. These two cases were assessed 
by the treating physician as not causally related to the study medication and not 
unusual considering the demographic background of the study population.
One limitation of our study is that it was not powered to detect a small effect of 
benfotiamine on urinary albumin excretion as an add-on therapy besides existing 
ACE-I or ARB treatment. Our study was explorative and used a one-sided hypothesis 
based on the likelihood of improvement in outcome measures. However, after 12 
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group versus -7 mg/24h in the placebo group. It is questionable whether such a 
difference would be considered clinically relevant and a much larger study would 
have been necessary to find this difference statistically significant.
In conclusion, 12-week treatment with benfotiamine in patients with type 2 diabetes 
and mild diabetic nephropathy did not reduce urinary excretion of albumin or 
tubulointerstitial damage markers. Long-term intervention studies are likely to be 
necessary to discern whether benfotiamine treatment has an effect on development 
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Chapter 7
Effects of benfotiamine treatment on advanced glycation 
endproducts and markers of endothelial dysfunction and 
inflammation in diabetic nephropathy
Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJG, Gans ROB, Heeringa P, 








































Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, 
and low-grade inflammation are intermediate pathways of hyperglycemia-induced 
vascular complications. We investigated the effect of benfotiamine on markers of 
these pathways in patients with type 2 diabetes and nephropathy.
Methods 
Patients with type 2 diabetes and urinary albumin excretion in the high-normal and 
microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine 
(n=39) or placebo (n=43). Plasma and urinary AGEs (Nε-(carboxymethyl)lysine 
[CML], Nε-(Carboxyethyl)lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) 
and plasma markers of endothelial dysfunction (soluble vascular cell adhesion 
molecule-1 [sVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1], soluble 
E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], 
serum amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and 
after 6 and 12 weeks.
Results 
Compared to placebo, benfotiamine did not result in significant reductions in 
plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade 
inflammation.
Conclusions








































Diabetic nephropathy (DN) is a serious complication of diabetes and a leading cause 
of end-stage renal disease [1]. Thiamine and benfotiamine, a lipophilic thiamine-
derivative, have been suggested as novel therapies for diabetic complications, 
including DN [2]. These agents would not exert their beneficial effects by improvement 
of hyperglycemia itself, but rather by activation of transketolase [2, 3]. This leads to a 
decrease in triosephospates and methylglyoxal; i.e. the major precursors of advanced 
glycation endproducts (AGEs), and subsequently inhibition of endothelial dysfunction 
and chronic low-grade inflammation [4, 5]. However, in a recent 12-week double-
blind placebo-controlled trial in patients with type 2 diabetes, we found no effect of 
benfotiamine on urinary albumin excretion (UAE) or renal tubular damage markers 
[6]. One possibility is that our choice for these primary endpoints is too late in the 
sequence of events, because even the reduction in AGEs that occurs after pancreas 
transplantation has been reported to take years to translate into an effect on urinary 
albumin excretion [7]. We now aimed to evaluate the effect of benfotiamine on AGEs 
and markers of endothelial dysfunction and chronic low-grade inflammation, and to 
find ground to set up a study of longer duration.
Methods
Patients and study design
A detailed description of the study has been published [6]. We included patients 
from the outpatients department in the Isala Clinics, Zwolle, the Netherlands, in 
the period from January 2008 till June 2009. Included subjects were patients with 
type 2 diabetes, aged 40 to 75 years, with UAE between 15-300 mg/24h despite 
treatment with ACE inhibitors (ACE-Is) and/or angiotensin receptor blockers (ARBs). 
Patients (n=86) were randomized to receive either benfotiamine (Wörwag pharma, 
Böblingen, Germany) 300mg t.i.d. (total daily dose 900mg) or placebo during 12 
weeks. On each visit (baseline, 6 weeks, and 12 weeks), patients delivered 24-h 
urine collection, and additional morning spot-urine and blood samples were taken. 





































the Helsinki Declaration and approved by the Medical Ethics Committee of the Isala 
Clinics, Zwolle, the Netherlands.
Clinical laboratory investigations
For the current report, urine and plasma samples were stored frozen at -80°C 
until assessment. Detection of plasma AGEs Nε-(carboxymethyl)lysine (CML), 
Nε-(Carboxyethyl)lysine (CEL) and urine AGEs (CML, CEL and the methylglyoxal-
arginine-adduct 5-hydro-5-methylimidazolone (MG-H1)) in 24-h urine samples 
was performed by means of a stable-isotope-dilution tandem mass spectrometry 
method [8, 9]. Soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble 
intercellular adhesion molecule-1 (sICAM-1), high sensitivity C-reactive protein (hs-
CRP) and serum amyloid-A (SAA) were assessed by multi-array detection system 
(SECTOR-Imager 2400, Mesoscale Discovery, Maryland). Soluble E-selectin and 
myeloperoxidase (MPO) were measured by commercially available multiplex assays 
(Millipore, Massachusetts). Other measurements were performed according to 
standard hospital procedures.
Statistical analysis
Variables with a normal distribution are presented as mean and standard deviation 
and variables with a skewed distribution are presented as median and interquartile 
range. Intention-to-treat analysis and per-protocol analysis were planned. After 
randomization, four patients from the benfotiamine group withdrew from consent. 
Therefore, these subjects were not available for follow-up visits and no samples 
could be obtained from these subjects. All remaining patients (39 patients in 
the benfotiamine group and 43 patients in the placebo group) were available for 
analyses. In per-protocol analyses, patients who deviated from the study protocol 
(non-compliance or change in concomitant medications, n = 1 in the benfotiamine 
group and n = 3 in the placebo group [6]) were excluded. In the previous report [6], 
analyses of the primary endpoints (UAE and KIM-1) were presented. In this report, we 
present predefined analyses of secondary endpoints: plasma and urinary AGEs and 
plasma levels of biomarkers of endothelial dysfunction and low-grade inflammation. 
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factors (effect of time; disease modifying model), effects of the between-subjects 
factors (difference between groups; symptomatic relief), and interaction between 
time of visit (0, 6, and 12 weeks) and group (benfotiamine versus placebo) were 
evaluated. Q-Q plots were used to assess whether the residuals of the dependent 
variables in the model had normal distribution. Because of skewed distribution of the 
residuals, logarithmic transformation (natural logarithm) of the data was performed 
before analysis. The results are summarized in terms of estimated means with 95% 
confidence intervals (CI). Differences in mean change between benfotiamine and 
placebo at 6 weeks and 12 weeks are presented as mean difference with 95% CI. 
P-values for time, group, and time*group interaction are presented. A two-sided 
P-value <0.05 was considered statistically significant. Statistics were done with SPSS, 
version 16.0 (Chicago, IL).
Results
Baseline characteristics are presented in table 1. At baseline, blood thiamine was 
correlated with urinary excretion of CML (r=0.26, P=0.02) and CEL (r=0.25, P=0.02). No 
significant correlations of thiamine status with other AGEs or biomarkers of endothelial 
dysfunction and low-grade inflammation were found. Baseline characteristics were 
not materially different between groups, except for a more frequent use of oral 
hypoglycaemic agents and a slightly higher plasma creatinine in the placebo group. 
As shown in table 2, benfotiamine treatment had neither a significant effect on 
plasma or urinary AGEs nor on markers of endothelial dysfunction or chronic low-
grade inflammation. Adjustment for baseline differences gave similar results. Results 
of per-protocol analysis (not shown) were not different from presented intention-to-
treat analyses. Subgroup analyses in patients with low range UAE (<100 mg/24u) and 






































Table 1: Baseline characteristics of study population
Benfotiamine (n = 39) Placebo (n = 43)
Males (n (%)) 30 (77%) 33 (82%)
Age (years) 65.3 ± 5.9 64.6 ± 6.1
BMI (kg/m2) 32.1 ± 5.1 31.9 ± 5.9
Duration of diabetes (years) 12 [9; 18] 10 [7; 18]
SBP (mmHg) 140 ± 16 137 ± 20
DBP (mmHg) 67 ± 8 76 ± 10
A1c (%) 7.3 ± 0.9 7.4 ± 0.9
Plasma creatinine (μmol/l) 84 ± 19 87 ± 23
UAE (mg/24h) 90 [38; 267] 97 [48; 177]
Thiamine (nmol/l) 126 ± 23 122 ± 23
Plasma AGEs
CML (nmol/mmol lysine) 64.48 [58.21; 69.69] 62.51 [54.88; 71.20]
CEL (nmol/mmol lysine) 51.14 [44.78; 59.25] 56.99 [43.71; 62.10]
urine AGes
CML excretion (nmol/24h) 7630 [6761; 10576] 8879 [6476; 11769]
CML/creatinine (nmol/mmol) 572 [416; 731] 596 [483; 788]
CEL excretion (nmol/24h) 12405 [9105; 15240] 11204 [8922; 16384]
CEL/creatinine (nmol/mmol) 763 [602; 1061] 871 [648; 1034]
MG-H1 excretion (nmol/24h) 479122 [34431; 69775] 44930 [32095; 58614]
MG-H1/creatinine (nmol/mmol) 3459 [2196; 4856] 2999 [2260; 4563]
Endothelial dysfunction markers
s-ICAM (ng/ml) 257.3 [222.0; 281.1] 241.7 [213.2; 308.0]
s-VCAM (ng/ml) 399.1 [362.7; 431.7] 388.3 [335.8; 461.9]
s-E-Selectin (ng/ml) 45.3 [29.8; 54.6] 39.5 [26.8; 51.3]
Low-grade inflammation markers
Hs-CRP (ng/ml) 1395 [754; 2891] 1738 [824; 4097]
SAA (ng/ml) 1356 [927; 2028] 1162 [694; 2328]
MPO (ng/ml) 20.4 [9.9; 28.3] 20.4 [6.2; 27.2]
Data are mean ± standard deviation or median [interquartile range].
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; A1c, 
Glycated haemoglobin; UAE, urinary albumin excretion; AGEs, advanced glycation 
endproducts; CML, Nε-(Carboxymethyl)lysine; CEL, Nε-(Carboxyethyl)lysine; MG-H1, 5-hydro-
5-methylimidazolone; s-ICAM, serum inter-cellular adhesion molecule-1; s-VCAM, serum 
vascular cell adhesion molecule-1; Hs-CRP, high sensitive C-reactive protein; SAA, serum 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We found that 12-week treatment with benfotiamine in patients with type 2 diabetes 
did not result in a decrease of plasma AGEs, urinary excretion of AGEs, plasma 
biomarkers of endothelial dysfunction or plasma biomarkers of chronic low-grade 
inflammation.
Benfotiamine is converted to thiamine pyrophosphate, a co-factor of transketolase. 
The activation of transketolase plays a crucial role in oxidative and non-oxidative 
pentosephosphate pathways that inhibit vascular complications of diabetes [3, 10]. In 
our trial, although we found that benfotiamine resulted in a significant improvement 
in thiamine status (a significant increase in thiamine levels and transketolase activity), 
there was no significant difference between the benfotiamine group and the placebo 
group regarding urinary albumin excretion, urinary excretion of tubular damage 
markers, or blood pressure [6].
Studies in diabetic animals have shown that benfotiamine inhibited protein kinase 
C, formation of AGEs and oxidative stress, indicating a protective effect against 
hyperglycemia-induced endothelial dysfunction and inflammation [2, 4].
To the best of our knowledge, our study is the first randomised controlled trial 
that has investigated the effect of benfotiamine on AGEs formation and markers of 
low-grade inflammation in humans. Results from previous studies on thiamine and 
benfotiamine on endothelial function in humans are conflicting. An earlier cross-
sectional analysis in 74 patients with type 1 and type 2 diabetes found an inverse 
association of thiamine status with sVCAM-1 [11], suggesting an effect of thiamine 
status on markers of endothelial dysfunction. However, in a study in patients with 
type 2 diabetes [5], the same group found no effect of thiamine supplementation on 
sVCAM-1, We also did not find an effect of benfotiamine on markers of endothelial 
dysfunction, including sVCAM-1. Nevertheless, in a study in 13 patients with type 2 
diabetes [12], beneficial effects of benfotiamine (1050mg/day) on the endothelial 
damage and oxidative stress that occurs after consumption of an AGE-rich meal were 
suggested to be already present after three days of treatment. While on the basis 
of this experiment longer periods of treatment with benfotiamine (12 weeks in our 





































and endothelial damage, the effects of benfotiamine could also be more directly 
meal-related rather than affecting steady-state concentrations.
Compared to previous studies in animals [2] and humans [5, 13], a daily dose of 900 mg 
is considered as a high dose. Due to its pharmacokinetics, benfotiamine is absorbed 
considerably better than thiamine. However, it is important to realize that intestinal 
and renal tubular transport of thiamine is tightly regulated to maintain homeostasis. 
Accordingly, expression of the transporters is up-regulated in presence of deficiency 
states and down-regulated in response to an excess supply of these nutrients, which 
may account for a rapid excretion of thiamine in the urine after consumption of a 
high dose of benfotiamine [14, 15]. Additionally, studies in experimental animals 
have shown that chronic kidney disease results in down-regulation of expression 
of key transporters and receptors for thiamine and folate, which can further limit 
the bioavailability of these micronutrients [16]. In our study, although higher blood 
thiamine levels and transketolase activity was achieved in the benfotiamine group, 
thiamine levels in renal cells might still be deficient even in case of high blood thiamine. 
Our objectives were studied in a relevant study population, including patients with 
type 2 diabetes and UAE in the high-normal and microalbuminuric range treated 
with ACE-Is and/or ARBs. An important limitation of this study is that AGEs and 
biomarkers of endothelial dysfunction and inflammation were measured in urine and 
blood. Intracellular concentrations of these markers in target organs (e.g. glomeruli 
and tubuli) may give additional information on effects of benfotiamine on vascular 
complications. Therefore, assessment of intracellular AGEs in future studies would 
be necessary.
In conclusion, 12-week benfotiamine treatment did neither significantly affect 
plasma or urine AGEs nor plasma biomarkers of endothelial dysfunction or chronic 
low-grade inflammation in patients with type 2 diabetes and UAE in the high-normal 
and microalbuminuric range. Because small short-term effects can not be excluded 
and potential effects that take long to ensue can not be studied in a 12-week study, 
larger or longer term studies are necessary to elucidate whether benfotiamine 
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Early detection of patients at risk for diabetic nephropathy is possible by various 
means, but still, disease progression occurs despite an array of different treatments. 
Therefore, new and earlier markers for risk stratification and alternative therapeutic 
strategies are needed. This can offer a possibility to start early with effective 
treatment in high-risk patients, and thereby could prevent renal function loss and 
the deterioration towards end-stage renal disease (ESRD) in patients with diabetes. 
In this thesis, two novel approaches for risk stratification in diabetes were evaluated, 
namely risk assessment by genetic factors, and risk assessment by urinary proteomics. 
Additionally, it was investigated whether treatment with benfotiamine, addressing 
thiamine-related pathways as a novel therapeutic target, could be a beneficial 
intervention for diabetic nephropathy in patients with type 2 diabetes.
Risk stratification: genetics
For genetic risk stratification, we used a candidate gene approach. Accordingly, the 
investigated genes were selected based on previous studies suggesting relevance of 
the genotype in known pathways of progressive renal damage and its complications 
in diabetes. The first investigated gene is the carnosinase gene CNDP1. This gene is 
of interest because prior cross sectional studies in patients with type 1 and type 2 
diabetes suggested that CNDP1 could be a susceptibility locus of diabetic nephropathy 
[1, 2]. Homozygosity for five copies of a trinucleotide repeat encoding leucine (5L-5L) 
in CNDP1 was more common in patients without nephropathy, while other genetic 
variants of CNDP1 (e.g., variants with more leucine repeats: 5L-6L, 6L-6L, 6L-7L, 5L-7L 
or 7L-7L) were more common in patients with diabetic nephropathy. These findings are 
consistent with a protective role of the 5L-5L genotype against diabetic nephropathy 
[1-4]. However, a recent cross sectional study in patients with type 2 diabetes found 
the association between 5L-5L genotype and a reduced prevalence of diabetic 
nephropathy to be limited to women [4]. Findings from cross-sectional studies could 
be subject to selection bias that might results from a possible interaction of the 5L-5L 
genotype with diabetic nephropathy and/or sex for prediction of mortality. If survival 
disadvantage in a subgroup exists, it may induce false associations in cross-sectional 
studies [5]. In chapter 2, we presented a prospective study in Caucasian European 





































and 1170 controls without diabetic nephropathy). We aimed to investigate whether 
the 5L-5L homozygous genotype of CNDP1 was prospectively associated with 
progression to ESRD or mortality in patients with diabetes, and whether any of these 
associations were sex-specific. Leucine repeats were assessed with a fluorescent DNA 
analysis system. The median follow-up period was 8.8 years. When looking at short- 
term follow-up, we found that the risk of progression from diabetic nephropathy to 
ESRD (defined as need to start chronic dialysis or kidney transplantation) was not 
significantly different in patients with 5L-5L genotype compared to other genotypes. 
However, beyond 8 years of follow-up, patients with 5L-5L genotype had a higher risk 
of developing ESRD compared to patients with other genotypes. No interaction was 
found between CNDP1 and sex regarding progression to ESRD. Regarding the risk of 
mortality, there was no difference between 5L-5L genotype and other genotypes. 
We concluded that the homozygous genotype 5L-5L of CNDP1 was not associated 
with mortality, but confers increased risk of progression from nephropathy to ESRD 
in patients with type 1 diabetes after long-term follow-up.
In chapter 3, we investigated the same polymorphism in 871 patients with type 2 
diabetes with a follow-up of 9.5 years. In this study, we used individual slopes of renal 
function, expressed as estimated glomerular filtration rate using Modification of 
Diet in Renal Disease equation (eGFR-MDRD) [6]. We found no significant difference 
between patients with 5L-5L genotype compared to other genotypes regarding 
progression of renal function loss. CNDP1 polymorphism was not associated with all-
cause mortality. However, women, not men, with 5L-5L genotype had a higher risk of 
cardiovascular mortality compared to women with other genotypes. We concluded 
that in patients with type 2 diabetes, CNDP1 predicts cardiovascular mortality in a 
sex-specific manner, with a higher risk in women with 5L-5L genotype compared to 
women with other genotypes.
The mechanism by which CNDP1 may reduce risk for diabetic nephropathy as was 
observed in earlier cross-sectional studies could be through protective effects of 
lower carnosinase activity in patients with 5L-5L genotype. The number of leucine 
repeats in CNDP1 has been found to influence serum carnosinase activity, with the 
lowest activity measured in individuals with homozygosity for five leucine repeats 






































occurring dipeptide with protective actions, such as scavenging of free oxygen 
radicals and inhibition of formation of advanced glycation endproducts (AGEs) [7, 
8]. It was therefore hypothesized that subjects with 5L-5L genotype would have 
higher concentrations of serum carnosine, responsible for the suggested protective 
role of 5L-5L genotype against diabetic nephropathy. The different impact of CNDP1 
polymorphism in women compared to men was suggested to underlie the sex-specific 
association of CNDP1 and diabetic nephropathy. Since men have higher carnosine 
levels in muscles and women have higher serum carnosinase levels, differences in 
carnosinase activity due to the different CNDP1 polymorphism may have a stronger 
impact in women [9]. However, the suggested effect of 5L-5L in diabetic nephropathy 
is still a subject of debate. Although genetic variability in CNDP1 has been shown 
to influence glucose metabolism, animal experiments and other human studies 
failed to confirm an association between CNDP1 and diabetic nephropathy [8, 10, 
11]. If the finding in chapter 3 on increased cardiovascular mortality in women with 
5L-5L compared with other genotypes is replicated, I can speculate that survival 
disadvantage in women with 5L-5L and nephropathy may have resulted in a lower 
number of women with 5L-5L and nephropathy than the number of women with 
other genotypes and nephropathy included in cross-sectional studies. This may have 
induced false associations in previous cross-sectional studies.
The discrepancy between our findings and findings from previous cross-sectional 
studies may also be explained by other factors. First, it is important to realize that we 
investigated clinical endpoints, i.e., ESRD and mortality, while cross sectional studies 
only looked at an association with diabetic nephropathy. In late stages of diabetic 
renal disease, many other risk factors besides genetic predisposition can overrule 
the role of a single polymorphism, especially when the suggested role is relatively 
small and supposed to modulate early pathways of vascular damage. Second, other 
genetic risk alleles for diabetic nephropathy in the same region of chromosome 18, 
or even other chromosomes, may play an important role in predicting risk of diabetic 
nephropathy. Indications for this suggestion have indeed been found in other studies 
[10, 12]. Third, the associations from cross-sectional studies have been proposed to 
be the consequence of a primary effect of carnosine on glucose metabolism [1, 7]. In 





































functional indicators of glucose metabolism in mice [8]. Taking into consideration that 
diabetic renal disease is a multi-factorial phenomenon that results from activation 
of multiple cascaded of pathways, the role of genetic variation in CNDP1 could be 
more pronounced in the early phase of diabetic renal disease, possibly even before 
albuminuria is established. At this moment, there are no prospective studies on the 
role of CNDP1 polymorphism in development of new-onset albuminuria and diabetic 
nephropathy. Such studies are necessary to evaluate the clinical relevance of the 
CNDP1 polymorphism in diabetic nephropathy.
The second investigated gene in this thesis is CCR2. In chapter 4, we prospectively 
investigated whether CCR2 V64I polymophism, together with ACE I/D, predict the 
development of new-onset microalbuminuria in patients with type 2 diabetes. 
These genes are of interest because they have been implicated in renin-angiotensin-
aldosterone system (RAAS) and the inflammatory pathways in several populations 
[13, 14]. The ACE I/D polymorphism in the angiotensin-converting enzyme (ACE) 
gene has been widely investigated as a potential risk factor for diabetic nephropathy 
[15, 16]. Activation of RAAS and the resulting renal hemodynamic changes modify 
the growth and activity of glomerular cells, inducing the expression of chemokines 
with direct pro-fibrotic and pro-inflammatory responses [17, 18]. Monocyte 
chemoattractant protein-1 (MCP-1), activated by its C-C chemokine receptor 
(CCR2), is an essential chemokine that is implicated in chronic monocyte-mediated 
inflammation and endothelial damage [19]. Recent animal experimental and clinical 
studies have suggested CCR2 and its gene to play a role in the inflammatory pathways 
in vascular diseases [20, 21]. Furthermore, CCR2 V64I polymorphism has been shown 
to be associated with coronary artery disease [13, 14]. Therefore, we hypothesized 
that the CCR2 V64I polymorphism could play a role in the development of diabetic 
nephropathy. ACE I/D and CCR2 V64I were genotyped by agarose gel electrophoresis 
and sequences analysis respectively in 1128 patients from the BErgamo NEphrologic 
Diabetic Complications Trial (BENEDICT) – a prospective randomized trial evaluating 
ACE inhibition (ACE-I) effect on new-onset microalbuminuria (albuminuria 20-200 
µg/min) in hypertensive type 2 diabetes patients without albuminuria (<20 µg/
min) at inclusion. Median follow-up was 42.3 months. We found that ACE I/D was 






































significantly associated with new-onset microalbuminuria. The risk of development 
of microalbuminuria was higher in patients with combined mutant genotypes from 
both polymorphisms, i.e. DD from ACE I/D and VI/II from CCR2, compared to carriers 
of neither of these genotypes, i.e. ID/DD and VV. Thus, we were able to confirm earlier 
findings on the role of ACE I/D polymorphism as a genetic risk factor for diabetic 
nephropathy and concluded that CCR2 V64I polymorphism may have additional 
value besides ACE I/D polymorphism on prediction of renal outcome in patients with 
diabetes. We did not find a significant interaction between ACE-I treatment and ACE 
I/D or CCR2 V64I.
In the RENAAL study, the unfavorable renal prognosis conferred by the D allele of ACE 
I/D polymorphism was opposed by treatment with Losartan in patients with type 2 
diabetes [22], In contrast to these findings, we found that treatment with ACE-I was 
homogeneously renoprotective in all patients, regardless of their ACE I/D genotype. 
This could be explained by difference in stage of nephropathy between the population 
of the RENAAL study and the investigated population in chapter 4. All patients in 
our study were normoalbuminuric at the beginning of the trial, whereas patients 
in the RENAAL study had advanced diabetic renal disease with macroalbuminuria. 
Therefore, additional benefit of RAAS-blockade in patients with D allele of ACE I/D 
seems to be prominent only in later stages of diabetic nephropathy.
Risk stratification: urine proteomics
In the last decade, analysis of urinary proteins using capillary electrophoresis coupled 
with mass spectrometry (CE-MS) has helped to investigate important biomarkers 
for diabetic nephropathy [23, 24]. Using such data, a model including 65 urinary 
biomarkers for diabetic nephropathy has been developed in patients with type 1 
diabetes [25]. This model was able to distinguish patients with diabetic nephropathy 
with 97% sensitivity and specificity (AUC = 0.994). However, this model has not been 
externally validated in patients with type 2 diabetes. Validation is required before 
implementation of this model in clinical practice [26]. In chapter 5, we evaluated 
the validity of the previously established proteomic biomarkers with respect to the 
diagnostic potential in 148 Caucasian patients with type 2 diabetes. Cases were 





































mg/24h, diabetic retinopathy and at least 5 years duration of diabetes. Controls were 
patients with diabetes without nephropathy, defined as at least 5 years duration of 
diabetes without nephropathy (no albuminuria). In this blinded case-control study, 
proteome analysis was performed using high-resolution capillary electrophoresis 
coupled with mass spectrometry (CE-MS). Evaluation of data was performed using 
the previously developed model for diabetic nephropathy. We found this model to 
have 93.8% sensitivity and 91.4% specificity in the selected cohort of patients with 
type 2 diabetes, with a combined AUC of 0.95. We concluded that urinary proteome 
analysis by CE-MS is able to distinguish patients with diabetic nephropathy from 
normoalbuminuric diabetic patients.
This study did not include patients with microalbuminuria and did not have a 
longitudinal part, so the diagnostic value of proteome analysis in detection early 
stages of diabetic nephropathy was not investigated. These limitations have been 
covered in recent studies on the assessment of urinary collagen fragments in 
detection of early stages of diabetic nephropathy. Indeed, shortly after our study, a 
study by Good et al. [27] reported a model based on 273 urinary biomarkers, the so-
called CKD273 classifier. This model was shown to have high sensitivity and specificity 
in detection of chronic kidney disease, irrespective of the underlying pathology. 
Recently, the CKD273 classifier was prospectively investigated and could identify 
patients with diabetes who will develop diabetic nephropathy 3-5 years before 
the development of microalbuminuria [28]. In this study, there was a decrease in 
collagen fragments before albumin excretion started to increase. It was speculated 
that the decrease in collagen fragments observed early in the course of diabetic 
nephropathy could be the related to the increase in extracellular matrix deposition 
associated with hyperglycemia-induced vascular damage [29]. Therefore, analysis of 
urinary proteomics seems to be a promising method in assessment of patients at risk 
for diabetic nephropathy at an early stage.
Benfotiamine; a beneficial treatment for diabetic nephropathy?
In animal experimental studies, benfotiamine and thiamine have been suggested 
as agents that can prevent occurrence and deterioration of diabetic complications 






































transketolase (TK), thiamine and benfotiamine are supposed to be responsible 
for countering the adverse effect of hyperglycemia: activation of hexosamine and 
protein kinase C (PKC) pathways, mitochondrial dysfunction and formation of AGEs 
[30, 32]. These pathways are implicated in glucose-mediated vascular damage that 
underlies diabetic complications, including diabetic nephropathy [33]. Therefore, in 
chapter 6, we investigated the effect of benfotiamine on urinary excretion of albumin 
(UAE) and the tubular damage markers; kidney injury molecule-1 (KIM-1) and α-1 
microglobulin, in patients with diabetic nephropathy. Eighty-six patients with type 
2 diabetes and UAE equivalent to 15-300 mg/24h, despite angiotensin-converting 
enzyme inhibitors (ACE-Is) or angiotensin-receptor blockers (ARBs), were randomly 
assigned to 12-week benfotiamine (900mg/day) or placebo. Despite a significant 
improvement in thiamine status and TK activity in the benfotiamine-group, we found 
that 12-week treatment with benfotiamine did not result in a decrease in urinary 
excretion of albumin, KIM-1 or α-1 microglobulin compared to placebo. Regarding 
other clinical parameters, benfotiamine resulted in a small increase in plasma 
creatinine compared to placebo. We concluded that in patients with type 2 diabetes 
and nephropathy, high-dose benfotiamine treatment for 12 weeks as add-on to ACE-
Is or ARBs did not reverse albuminuria or tubular damage. 
As suggested by animal studies, thiamine and benfotiamine are supposed to 
antagonize detrimental effects of hyperglycemia on tissues, including the formation 
of AGEs, endothelial damage, and low-grade inflammation [30, 34]. Given the fact 
that we did not find an effect of benfotiamine on a more distant outcome parameter, 
such as albuminuria, we wondered whether benfotiamine had effect on parameters 
that are supposed to be more directly affected by benfotiamine. Therefore, in 
chapter 7 we investigated the effect of benfotiamine on markers of these pathways 
in patients with type 2 diabetes who participated in our randomized controlled 
trial on benfotiamine in diabetic nephropathy. AGEs (Nε-(carboxymethyl)lysine 
[CML], Nε-(Carboxyethyl)lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) 
were measured in plasma and urine at baseline and after 6 and 12 weeks. Plasma 
markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 
[sVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1], soluble E-selectin) 





































CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]) were also measured at 
baseline and after 6 and 12 weeks. Compared to placebo, benfotiamine did not 
result in significant reductions in plasma or urinary AGEs, plasma markers of 
endothelial dysfunction, or low-grade inflammation. We concluded that 12-week 
treatment with benfotiamine did not affect intermediate pathways that could 
finally lead to hyperglycemia-induced vascular complications, including albuminuria. 
Our findings differ from an earlier pilot study in 40 patients with type 2 diabetes 
in which 12 weeks of 300mg/day of thiamine resulted in a significant decrease in 
UAE of 17.7mg/24h [35]. In that study, baseline UAE was 44 [33-121] mg/24h in 
the thiamine and 51 [32-122]mg/24h in the placebo group, which is almost two 
times lower than in our study, despite 100% of ACE-I/ARB treatment in our study 
versus <50% in the pilot study. Thus, thiamine and benfotiamine might prove to have 
protective effects in earlier diabetic nephropathy stages or in patients without any 
other form of renoprotective treatment. This is in line with an animal study in which 
development of albuminuria after induction of diabetes was inhibited by thiamine 
and benfotiamine [31].
One possible explanation for the lack of effect of benfotiamine could be the short 
duration of treatment in our trial. For example, in two large intervention studies, 
it took years of lowering HbA1c before difference in UAE was found between strict 
metabolic control and standard therapy [36, 37]. Similar delay was found in patients 
after pancreas transplantation, in whom it took at least five years of normalization 
of glucose concentrations by pancreas transplantation before glomerular lesions 
disappeared and albuminuria decreased [38]. The fact, however, that we did not find 
an effect of benfotiamine on intermediate pathways , including formation of AGEs, 
endothelial damage, and inflammation, makes it less likely that benfotiamine would 
have effects in studies of longer duration.
Strengths and limitations
The strengths of the studies on genetic risk stratification in chapter 2, 3 and 4 are their 
prospective design, the long duration of follow-up, and the well-defined clinically 
relevant endpoints. The studies on CNDP1 and CCR2 V64I are the first and the largest 






































prospective study was performed on CNDP1 in patients with type 1 diabetes and found, 
in line with our findings, no significant association between CNDP1 polymorphism 
and progression to ESRD [11]. In the studies on CNDP1, besides progression to ESRD, 
we investigated the risk of mortality as a relevant prognostic endpoint. Only in 
female patients with type 2 diabetes, CNDP1 predicted cardiovascular mortality with 
increased risk in those with 5L-5L genotype compared to other genotypes. This finding 
could clarify the sex-specific correlation found in a previous cross-sectional study. 
Selection bias in cross-sectional studies remains a major pitfall of this kind of studies. 
This is because cardiovascular mortality can be considered as a competing risk for 
the development of diabetic nephropathy and ESRD in patients with nephropathy. 
Another strength of the prospective studies on novel genes is that we tested the 
proportional hazard (PH) assumption before we applied Cox regression analyses. The 
PH assumption must be tested for each variable before variables can be included in a 
Cox regression model. If not, models with time-dependent covariates should be used 
to estimate hazard ratios [39]. For our studies, we used the tests for non-zero slope 
of scaled Schoenfeld residuals for functions of time [40]. In these analyses, CNDP1 
polymorphism turned out to have a time-dependent association with progression of 
ESRD in patients with type 1 diabetes. One possible explanation for this pattern of 
association is gene-environment interaction which may alter over time. Factors such 
as glycemic control have indeed been shown to play a role in secretion of carnosinase 
and its activity [41]. 
The studies in chapter 2, 3 and 4 also have limitations. First, data on changes in clinical 
parameters (HbA
1c, blood pressure, cholesterol level, and cardiovascular status) and 
use of medication during follow-up were not always available. These factors have 
influence on the risk of albuminuria, ESRD and mortality. Therefore adjustment for 
these confounders was not always possible. Second, no yearly measurements on 
true GFR were performed during follow-up in studies on CNDP1 in chapter 3. As an 
alternative, we used the estimated GFR as calculated by the MDRD-formula in order 
to calculate the individual slopes of renal function in patients with type 2 diabetes. 
Thus, some caution is warranted when interpreting the results on slopes of eGFR-
MDRD, taking the limitations of the MDRD formula as an estimate of true GFR into 





































renal function decline in patients with progressive renal disease [42, 43]. Thirdly, 
follow-up data on yearly urinary albumin excretion were not available in many of 
the included patients. Therefore, the question whether CNDP1 is associated with 
development or progression of albuminuria remained unanswered.
The strength of the clinical trial on benfotiamine lies in its design. We performed 
a randomized double-blind placebo-controlled clinical trial in patients with type 2 
diabetes. A power calculation was made to detect a relevant decrease in the primary 
outcome parameter (urinary albumin excretion). Patients were included after a 
screening period, in which albuminuria between 15-300 mg/24h was documented in 
at least 2 different measurements. Changes in antihypertensive treatment, especially 
ACE-I and/or ARB were not allowed in the screening period and during the study 
period, and patients were strictly controlled during the study and all changes in co-
medications were monitored. In addition to measuring parameters of renal damage in 
24-hour urine (albuminuria, tubular damage markers and AGE’s), we measured AGEs 
and parameters of endothelial dysfunction and inflammation in plasma. This enabled 
us to investigate possible effects of benfotiamine not restricted to the kidneys. 
Despite the many strengths of our benfotiamine trial, it still has limitations. First, we 
included patients with albuminuria ranging from 15 to 300 mg/24h under treatment 
with ACE-I and/or ARB, corresponding with high-normal and microalbuminuric range. 
Therefore, some patients (< 10%) did not have microalbuminuria at baseline, and 
without knowledge of the degree of albuminuria they would have had if they had 
not received ACE-I and/or ARB, an unknown part of these patients could in reality be 
normoalbuminuric, although on a whole this would probably be a very small portion. 
This could have resulted in lack of effect of benfotiamine in this subgroup, and thereby 
affecting to a small extent the general outcome. Since benfotiamine is supposed 
to influence intermediate pathways between hyperglycemia and microvascular 
complication, namely thiamine-induced pathways, we assumed the effect of 
benfotiamine to be more pronounced in patients with early diabetic nephropathy 
rather in those with advanced nephropathy. Subgroup analyses according to urinary 
albumin excretion (lower range and upper range) did not reveal a different response 






































Second, the trial was powered to detect a relevant decrease in urinary albumin 
excretion as primary study parameter. Finding no significant differences in secondary 
study parameters (AGEs, markers of endothelial dysfunction and inflammation) 
does not exclude effects of benfotiamine treatment on these parameters. However, 
looking at the measured differences between benfotiamine and placebo in our data, 
it seems that only small non-relevant differences could be present, if they would be 
present at all.
Third, power calculation was based on one side-testing to detect a relevant reduction 
(50% reduction) in urinary albumin excretion, since decrease, and not increase in 
urinary albumin excretion was hypothesized in our study. Thus, this study was not 
powered to detect a change but an improvement only in urinary albumin excretion 
in patients with benfotiamine compared with placebo. A design with 2-sided testing 
would have been preferable, however when interpreting the confidence intervals of 
the changes in the several outcome parameters, this probably would not have let to 
different conclusions.
SuMMARy AND FuTuRE PERSPECTIVES
In patients with type 1 diabetes, CNDP1 polymorphism predicts progression to 
ESRD, but not mortality. In patients with type 2 diabetes, CNDP1 polymorphism did 
not predict progression of decline of renal function. Cardiovascular mortality was 
increased in female patients with 5L-5L compared to other genotypes. These results 
seem to contrast with results of earlier cross-sectional studies. More prospective 
studies are required to finally be able to discern whether CNDP1 indeed plays a 
role as a susceptibility factor of diabetic nephropathy and progression of diabetic 
nephropathy to ESRD. Replication of the finding on increased risk of cardiovascular 
mortality in women with 5L-5L genotype, preferably in prospective studies, is 
needed to better understand the role of CNDP1 and serum carnosinase in diabetic 
complications. Another important question is the role of carnosine as a potential 
agent for pharmacological intervention, aimed at modifying glucose metabolism and 
possibly preventing diabetic vascular complication. Randomized controlled trial are 





































In this these I also confirmed the role ACE I/D polymorphism as a risk factor for 
development of new-onset albuminuria in patients with type 2 diabetes and 
concluded that CCR2 V64I polymorphism might have additional value besides ACE I/D 
polymorphism on predicting renal outcome. Larger prospective studies on CCR2 V64I 
polymorphism are needed to investigate its possible role in genetic risk assessment 
of diabetic nephropathy.
Analysis of urine proteomics by CE-MS is a helpful diagnostic tool for the detection 
of diabetic nephropathy. Other studies have shown that urinary proteomics enables 
noninvasive assessment of diabetic nephropathy risk at an early stage. In a recent 
study, treatment with ARB (Irbesartan) in patients with microalbuminuria has 
resulted in improvement in urine peptide identified by CE-MS analysis of urine 
proteomics [44]. Therefore, it is tempting to speculate that using urine proteomics, 
renoprotective treatment could be early initiated in those at risk to develop diabetic 
nephropathy in order to delay or prevent development of microalbuminuria. This 
subject should be further investigated in upcoming trials. Before urine proteomics 
becomes a part of screening in patients with diabetes, further research will be 
necessary to investigate prognostic value above albuminuria and cost-effectiveness 
of proteome analysis by CE-MS in diabetic renal disease, ESRD and (cardiovascular) 
mortality.
Based on our randomized controlled trial, our main conclusion is that a 12-week 
treatment with benfotiamine did not represent a beneficial intervention in patients 
with diabetic nephropathy. At this moment, based on the current evidence, there 
are no arguments to recommend the use of benfotiamine as a treatment for patients 
with diabetic nephropathy. Further research is necessary to elucidate whether 
longer-term treatment with benfotiamine or initiation of treatment in earlier stages 
before diabetic nephropathy is already established, could be a beneficial intervention 
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Dit proefschrift heeft drie doelen: (1) bestuderen van twee recent beschreven genen 
als risicofactoren voor het ontwikkelen van diabetische nefropathie, (2) onderzoeken 
of analyse van eiwitten in de urine (urine proteomics) geschikt is om diabetische 
nefropathie in een vroeg stadium te detecteren, en (3) onderzoeken of benfotiamine 
(een vetoplosbaar thiaminederivaat) een zinvolle behandeling is bij patiënten met 
diabetische nefropathie.
Risicostratificatie: genetica
De onderzochte genen zijn geselecteerd op basis van eerdere studies waarin een 
relevante associatie werd gevonden tussen de betreffende genen en cascades 
van nierschade in patiënten met diabetes. Hoofdstukken 2 en 3 gaan over het 
carnosinase-1 gen (CNDP1) op chromosoom 18. Enkele cross-sectionele studies in 
patiënten met type 2 diabetes suggereerden dat het aantal leucines in het CNDP1 
gen is geassocieerd met diabetische nefropathie. Uit die studie is gebleken dat 
patiënten die homozygoot waren voor het laagste aantal leucines (5L-5L) in CNDP1 
een lager risico op diabetische nefropathie hebben dan patiënten met een groter 
aantal leucines (5L-6L, 6L-6L, 5L-7L, 6L-7L, 7L-7L) in het CNDP1 gen. Dit verband 
wordt toegeschreven aan de rol van CNDP1 in het metabolisme van carnosine. Het 
genotype 5L-5L zou leiden tot een lagere activiteit van het enzym carnonisase in het 
serum, waardoor er meer carnosine beschikbaar is. Carnosine is een dipeptide met 
beschermende eigenschappen door het remmen van vrije radicalen en “advanced 
glycation endproducts (AGEs)”. Echter, selectiebias in cross-sectionele studies kan 
niet uitgesloten worden. Immers, prospectieve studies over CNDP1 ontbraken en 
enkele cross-sectionele studies hebben de hierboven beschreven associatie niet 
kunnen bevestigen. Tevens liet een recent onderzoek zien dat de associatie tussen 
CNDP1 en diabetische nefropathie is beperkt tot vrouwen met type 2 diabetes, 
waarbij gedacht werd aan een interactie tussen CNDP1 en sekse. Om deze redenen 
hebben wij CNDP1 in prospectieve studies onderzocht. In hoofdstuk 2 wordt de 
associatie tussen CNDP1 en het ontwikkelen van eindstadium nierfalen of mortaliteit 
bij 2086 patiënten met type 1 diabetes bestudeerd. De mediane follow-up duur was 
8.8 jaar. Het risico op eindstadium nierfalen na een lange follow-up was groter in 





































verschil in mortaliteit tussen de subgroepen en er was geen interactie tussen het 
gen en de sekse. In hoofdstuk 3 wordt CNDP1 bestudeerd in 871 patiënten met 
type 2 diabetes. De mediane follow-up duur was 9.5 jaar. Genetische variatie in 
CNDP1 was niet geassocieerd met de achteruitgang van nierfunctie of mortaliteit. 
Wel was het risico op cardiovasculaire mortaliteit in vrouwen met het 5L-5L 
genotype verhoogd in vergelijking met vrouwen met andere genotypen. Dit verband 
ontbrak bij mannen, passend bij een geslachtsafhankelijke relatie tussen CNDP1 
en cardiovasculaire mortaliteit bij patiënten met type 2 diabetes. Mogelijk heeft 
de hogere cardiovasculaire mortaliteit bij vrouwen met 5L-5L gezorgd voor een 
selectiebias in de cross-sectionele studies.
In hoofdstuk 4 wordt een “single nucleotide polymorphism” (SNP) in het CCR2 gen 
(CCR2 V64I) samen met het bekende SNP in het ACE gen (ACE I/D) besproken. Het SNP 
CCR2 V64I bleek geassocieerd te zijn met vasculaire schade en cardiovasculaire ziekten 
maar is niet eerder onderzocht bij patiënten met diabetes. Het DD genotype van het 
ACE I/D SNP is reeds beschreven als risicofactor voor progressie van nierziekten bij 
patiënten met diabetes. Onze prospectieve analyse bij een cohort van 1128 patiënten 
met type 2 diabetes laat zien dat ACE I/D is geassocieerd met hoge incidentie van 
microalbuminurie, terwijl er geen significante associatie werd gevonden tussen CCR2 
V64I en de incidentie van microalbuminurie. Een gecombineerde analyse van beide 
SNPs liet zien dat patiënten met beide gemuteerde varianten (DD in ACE en VI/II in 
CCR2) een licht verhoogd risico hebben op het ontwikkelen van microalbuminurie 
vergeleken met patiënten met geen van deze varianten. Echter, het verschil tussen 
de groepen was niet significant. Mogelijk heeft het CCR2 V64I een toevoegende 
voorspellende waarde boven het ACE I/D bij patiënten met diabetische nefropathie.
Risicostratificatie: urine-proteomics
Analyse van eiwitten en collageenfragmenten in de urine door middel van “capillary 
electrophoresis coupled with mass spectrometry (CE-MS)” heeft in de afgelopen jaren 
geleid tot het ontdekken van nieuwe experimentele urinemarkers van diabetische 
nefropathie. Zo werd een model ontwikkeld met 65 biomarkers die een hoge 
sensitiviteit en specificiteit hebben als het gaat om het voorspellen van nierschade 
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patiënten met type 2 diabetes om de diagnostische waarde van het 65-biomarker 
model te valideren. In deze geblindeerde case-control studie werd een analyse van 
eiwitten en collageenfragmenten in de urine (urine-proteomics) verricht en werd het 
65-biomarker model toegepast. Het model bleek een hoge sensitiviteit en specificiteit 
te hebben met betrekking tot het voorspellen van diabetische nefropathie bij 
patiënten met type 2 diabetes (AUC 0.95). Onze studie was de basis voor andere 
recente studies waarin een uitgebreid model werd ontwikkeld met 273 biomarkers. 
Dit model bleek een betere diagnostische en voorspellende waarde te hebben voor 
diabetische nefropathie in een vroeg stadium, namelijk voordat er albuminurie 
ontstaat. Mogelijk heeft deze ontwikkeling consequenties voor de praktijk. Zo zou 
een behandeling eerder gestart kunnen worden bij patiënten met een hoog risico op 
diabetische nefropathie. Gerandomiseerde trials moeten deze vraag beantwoorden.
Benfotiamine; een zinvolle behandeling bij patiënten met diabetische nefropathie?
In hoofdstukken 6 en 7 wordt de behandeling met benfotiamine bij patiënten met 
diabetische nefropathie besproken. Experimenten in proefdieren lieten zien dat 
benfotiamine en thiamine de nierschade en andere vasculaire complicaties van 
diabetes kunnen tegengaan of beperken. De activatie van het enzym transketolase 
door thiaminederivaten leidt tot een remming van de cascades die betrokken zijn 
bij de door hyperglycemie geïnduceerde vasculaire schade; namelijk activatie van 
hexosamine en protein kinase C (PKC), mitochondriale dysfunctie en formatie van 
AGEs. In hoofdstuk 6 wordt het effect van benfotiamine onderzocht bij 86 patiënten 
met type 2 diabetes en microalbuminurie in een gerandomiseerd dubbelblind 
placebo-gecontroleerd onderzoek. Alle geïncludeerde patiënten waren reeds 
ingesteld op een ACE-remmer en/of een angiotensine-receptor blokker (ARB). Na 12 
weken bleek de behandeling met benfotiamine geen verlagend effect te hebben op 
albuminurie of urinemakers van tubulointerstitiële nierschade. Omdat benfotiamine 
zou ingrijpen op de cascades die betrokken zijn bij de vasculaire schade hebben 
wij in hoofdstuk 7 een analyse uitgevoerd naar het effect van benfotiamine op de 
parameters van de hierboven genoemde cascades, zoals AGEs (Nε-(carboxymethyl)
lysine [CML], Nε-(Carboxyethyl)lysine [CEL] en 5-hydro-5-methylimidazolone [MG-





































cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion molecule-1 
[sICAM-1], soluble E-selectin) en inflammatie (high-sensitivity C-reactive protein 
[hs-CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]). Ook hierop werd geen 
effect van benfotiamine waargenomen ten opzichte van placebo na 12 weken van 
de behandeling.
De uitkomst van onze trial komt niet overeen met de bevindingen van de experimentele 
studies en een pilot-studie naar het effect van thiamine op albuminurie. Het stadium 
van de nefropathie ten tijde van het starten van de behandeling, de duur van de 
behandeling en het gelijktijdig gebruik van ACE-remmers en/of ARBs zijn factoren 
die mogelijk ten grondslag liggen aan de discrepantie tussen onze bevindingen en 
de eerdere bevindingen waarbij er een gunstig effect werd gezien van thiamine en 
benfotiamine op diabetische nefropathie. Bij een pilot-studie naar het effect van 
thaimine bij patiënten met type 2 diabetes uit Pakistan had minder dan 50% van 
de patiënten een ACE-remmer en/of een ARB. Dit kan van grote invloed zijn op de 
uitkomsten.
ConClusIe
Dit proefschrift laat zien dat het carnosinase-1 gen (CNDP1) voorspellend is voor het 
risico op eindstadium nierfalen bij patiënten met type 1 diabetes. In tegenstelling tot 
de bevindingen van cross-sectionele studies bij patiënten met type 2 diabetes, blijkt 
de homozygote variant voor het laagste aantal leucines (5L-5L) in het CNDP1 gen niet 
te beschermen tegen achteruitgang van nierfunctie bij patiënten met type 2 diabetes. 
Vrouwen met 5L-5L lijken een verhoogd risico op cardiovasculaire mortaliteit te 
hebben vergeleken met vrouwen met andere varianten. Deze bevinding kan van 
invloed zijn geweest op de resultaten van cross-sectionele studies. Replicatie van 
deze bevindingen in andere prospectieve studies is noodzakelijk om een beter inzicht 
te krijgen in de rol van carnosine en het carnosinase-1 gen (CNDP1) bij patiënten met 
diabetes.
In dit proefschrift heb ik de rol van ACE I/D SNP als genetische risicofactor voor het 
ontwikkelen van albuminurie bij patiënten met type 2 diabetes kunnen aantonen. 
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gebleken voor het risico op het ontstaan van albuminurie. Grotere prospectieve 
studies zijn nodig om de potentiële rol van CCR2 V64I in de inflammatoire cascade 
en als risicofactor voor nefropathie bij patiënten met diabetes in kaart te brengen.
Analyse van eiwitten en collageenfragmenten in de urine (urine-proteomics) is een 
bruikbare diagnostische methode voor diabetische nefropathie in vroeg stadium. 
Hierdoor is het in de toekomst wellicht mogelijk om patiënten met diabetes en een 
verhoogd risico op nefropathie tijdig te behandelen en regelmatig te controleren. 
Meer onderzoek is echter nodig om te kijken of het routinematige gebruik van urine-
proteomics bij patiënten met diabetes een zinvolle en kosteffectieve benadering is.
De laatste conclusie van mijn proefschrift luidt dat er geen bewijs is voor het 
gebruik van benfotiamine bij patiënten met type 2 diabetes, omdat het niet leidt tot 















































































Promoveren doe je niet alleen. Aan het einde van dit proefschrift is het moment 
aangebroken om de mensen te bedanken die achter (en voor!) de schermen 
betrokken waren bij de uitvoering van mijn onderzoek.
Te beginnen met de patiënten, die het grootste dankwoord verdienen, want zonder 
jullie deelname is er geen onderzoek mogelijk. 
Ook veel dank aan alle onderzoekers en medewerkers van het Universitair 
Medisch Centrum Groningen (de afdelingen Interne Geneeskunde - Nefrologie en 
het Labcentrum), de Isala Klinieken (Diabetes Kenniscentrum, afdeling Interne 
Geneeskunde, het Klinisch Chemisch Laboratorium en afdeling Maag-Darm-
Leverziekten), het Diaconnesenhuis Meppel (afdeling Interne Geneeskunde), het 
Academisch Ziekenhuis Maastricht (afdeling Interne Geneeskunde), het Steno 
Diabetes Centre (Gentofte, Denemarken) en het Mario Negri Institute (Bergamo, 
Italië), voor hun bijdrage aan de onderzoeken in dit proefschrift.
Verder wil ik een paar mensen in het bijzonder bedanken.
Prof. dr. G.J. Navis. Beste Gerjan, toen ik in 2007 voor het eerst bij jou langskwam 
om over onderzoek te praten (toen nog in het Engels!), wist ik eigenlijk nog niet 
zeker of ik wel wilde promoveren. Slechts een paar weken later zat ik midden in 
onderzoeksplannen waar ik jarenlang zoet mee zou zijn. Door jouw input en 
creatieve ideeën heeft mijn proefschrift een bijzonder internationaal karakter 
gekregen. Van Brussel (PREDICTIONS), langs Kopenhagen (EURAGEDIC), tot Bergamo 
(GENECURE), heb je altijd mooie onderzoeksmogelijkheden weten te vinden voor 
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